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Summary
The spread o f drug resistant strains of malaria parasites has made prophylaxis 
and treatment o f the disease increasingly difficult. The resistance o f 
Plasmodium falciparum  to chloroquine and sulfadoxine-pyrimethamine 
(Fansidar) has been reported in various parts o f Uganda.
A study was carried out in Tororo, Uganda, in order to investigate by 
polymerase chain reaction/dot-blot hybridisation the association o f mutations 
in the DIIFR  gene in Plasmodium falciparum  parasite isolates with clinical and 
parasitological treatment failure following sulfadoxine-pyrimethamine or a 
combination o f sulfadoxine-pyrimethamine and chloroquine treatment in 
Uganda. The study was also done to determine if the number o f mutations in 
DHFR is correlated with the time to recrudescence following sulfadoxine- 
pyrimethamine and sulfadoxine-pyrimethamine plus chloroquine treatment.
In collaboration with the Ministry of Health, blood samples were collected on 
filter paper on the first day of treatment-Day 0 (DO) and on any other day 
symptoms developed after administering Fansidar alone and a eombination of 
chloroquine and Fansidar to children with uncomplicated malaria aged between 
6 months and 5 years old who were followed up on days 1, 2, 3, 7, 14, 21 and 28. 
Forty seven paired chloroquine plus Fansidar DO and R (day o f recrudescence) 
patient DNA samples in the RI-RIII group, were genotyped at position 76 of the 
Pfcrt locus. Following genotyping at the M SPl and MSP2 loci, 22 of these 
patient samples showing evidence of recrudescence were genotyped at the 3 
DHFR codons: 108, 51 and 59. For Pfcrt codon 76, all (100%) of the pre- and 
post-treatment isolates possessed the Pfcrt T76 allele. Only 6 (13%) pre- and 3 
(7%) post-treatment isolates possessed both Pfcrt K76 and T76 alleles 
simultaneously. No isolate possessed only the Pfcrt K76 allele alone. For codon 
108, of the 22 (pre-treatment) patient DNA samples successfully typed, all 
(100%) had only the DHFR AsnlOS allele. The same trend was observed in the 
post-treatment isolates. No isolate pre- /or post-treatment possessed the DHFR 
Seri08 allele alone. No isolate pre- /or post-treatment possessed both DHFR 
SeiTOB and Asn 108 alleles simultaneously. At codon 51, there was a high
prevalence (96%) o f the 51 lie allele alone in the pre-treatment isolates and of the 
51Ile allele alone in the post-treatment isolates (100%). No isolate both pre- and 
post-treatment possessed the DHFR 51 Asn allele alone. Only one pre-treatment 
isolate possessed both DHFR 51 Asn and 51 He alleles simultaneously. At codon 
59 there was a low prevalence (14%) of the 59Arg allele alone in the pre­
treatment isolates and 38% of the isolates had the 59Arg allele alone in the post­
treatment isolates. Seventeen (77%) patient samples possessed both DHFR 
59Cys and 59Arg alleles present simultaneously in their pre-treatment isolates.
This dropped to 38% in the post-treatment isolates. Only 2 (9%) patient samples 
pre-treatment had only the 59Cys allele while this increased to 24% in the post­
treatment isolates.
Thirty three out of 48 paired Fansidar DO and R (day o f recrudescence) patient 
DNA samples in the RI-RIII group, showing evidence of recrudescence were 
genotyped for the 3 DHFR codons 108, 51 and 59. For codon 108, o f the 33 (pre- 
treatment) patient DNA samples successfully typed, all (100%) had only the 
DHFR AsnlOS allele. Thirty samples, representing 100% of the successfully 
typed post-treatment isolates, had only the DHFR AsnlOS allele. No isolate pre- 
or post-treatment possessed the DHFR SeiTOS allele alone. No patient pre- or 
post-treatment possessed both DHFR Seri 08 and Asn 108 alleles 
simultaneously. For codon 51, 100% of samples had only the DHFR 51 He allele 
in the pre-treatment isolates and 85% had only the DHFR 51 He allele in the post­
treatment isolates. No patient pre-treatment possessed the DHFR 51 Asn allele 
alone. Only one patient isolate post-treatment possessed the DHFR 51 Asn allele 
alone. One patient pre- and post-treatment possessed both DHFR 51 Asn and 
51 He alleles present simultaneously. At codon 59, there was a low prevalence 
(18%) of the 59Arg allele alone in the pre-treatment isolates and a high 
prevalence (77%) for 59Arg allele alone in the post-treatment isolates. Nineteen 
(58%) patient samples possessed both the DHFR 59Cys and 59Arg alleles 
present simultaneously in their pre-treatment isolates. This dropped to 17% in the 
post-treatment isolates. Only 8 (24%) patient samples pre-treatment had only the 
59Cys allele while this reduced to 7% in the post-treatment isolates. ^
:
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In conclusion, the findings showed there was no correlation between the 
presence of Pfcrt alleles encoding T76 and time to recrudescence following 
treatment with a combination of chloroquine and Fansidar. There was no 
correlation between the DHFR alleles encoding AsnlOS and/ or Iie51 and time 
to recrudescenee following treatment with chloroquine plus Fansidar as a 
combination and also with Fansidar treatment alone. There was however a 
correlation between the presence of the DHFR double mutant allele Asn 108/ 
Arg 59, and a stronger correlation between the triple mutant allele Asn 108/ He 
51/ Arg 59, and time to recrudescence following Fansidar treatment in Tororo, 
Uganda. There was no correlation of theses alleles in the chloroquine plus 
Fansidar treatment group.
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TIMING OF TREATMENT FAILURE AND MUTATIONS IN 
PLASMODIUM FALCIPARUM DIHYDROFOLATE REDUCTASE IN 
UGANDA
AIM: The aims o f  this thesis were
(i) To investigate the association o f mutations in dihydrofolate reductase 
{DHFR) with clinical and parasitological treatment failure following 
sulfadoxine-pyrimethamine (Fansidar-SP) or a combination o f SP and 
chloroquine (CQ) treatment (SP/CQ) in Uganda.
(ii) To determine if the number o f mutations in DHFR is correlated to the 
time to recrudescence following SP and the combination SP/CQ.
1. INTRODUCTION:
Malaria is caused by parasites o f the genus Plasmodium, protozoan parasites 
o f the blood. There are four species which affect man: P. falciparum, P. vivax, 
P. malariae and P. ovale. The virulence of P. falciparum, and its ability to 
develop drug resistance, marks it out from other species o f human malaria 
parasite as one o f  the main threats to global public health. Worldwide there are 
over 300-500 million new cases o f malaria per year which are responsible for
1.5 to 2.7 million deaths annually, mainly in children below 5 years o f age and 
pregnant women in sub-Saharan Africa (WHO Report, 2001). In Uganda, 
malaria is the principle cause o f death in children under 5 years and is 
responsible for 25% of all hospital admissions (Ministry o f Health) 
[http://www.health.go.ug/malaria.htm]). However, in many areas the 
effectiveness o f treatment and efforts to prevent falciparum  malaria are being 
limited by the development o f drug resistant strains (Peters, 1998). Although 
drug resistance is a major problem in other parts of the world, in Africa it is 
distinguished by two main factors: a) the enormous scale o f the disease (Snow 
et a l, 1999) and o f anti-malarial consumption for ‘fever’ and b) the small 
scale of the resources ranged against it.
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1.1 Definition of A ntim alarial drug  resistance
Antimalarial drug resistance has been defined as the “ability o f a parasite 
strain to survive and/ or multiply despite the administration and absorption o f 
a drug given in doses equal to or higher than those usually recommended but 
within tolerance o f the subject” (WHO, 1973).
This definition was later changed in reference to the drug in question by 
indicating that the drug must “gain access to the parasite or the infected red 
blood cell for the duration o f the time necessary for its normal action” (Bruce- 
Chwatt, 1986). This was interpreted by a majority o f other researchers to refer 
only to the persistence o f parasites after antimalarial treatment other than 
prophylaxis failure. The continued presence o f parasitaemia after antimalarial 
treatment is an indicator for early warning o f the occurrence o f drug resistance 
(LohoXet a l, 1986).
1.2 M alaria  trea tm en t failure
There are several factors that are able to contribute to malaria treatment failure 
including the following: incorrect dosing, non-compliance with duration of 
dosing regimen, poor drug quality, drug interactions, poor drug metabolism 
and misdiagnosis. These factors at the same time may contribute to the 
development and strength o f true drug resistance by elevating the rate at which 
the parasites are exposed to sub-optimal drug levels. Therefore, drug 
resistance can cause treatment failure but not all treatment failure is a result of 
drug resistance (Bloland, 2001).
Chloroquine (CQ) and the combination drug sulfadoxine-pyrimethamine (SP) 
are the commonest antimalarial drugs used in Uganda. Due to its reduced 
efficacy, CQ is no longer used as the first-line antimalarial drug in Uganda and 
in some other parts o f Africa. SP was one o f the most important second-line 
drugs used in Uganda for the treatment o f CQ-resistant P . falciparum  (Bloland 
et a l ,  1993). However, there are already anecdotal stories about SP resistance
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in several Ugandan urban populations (Staedke et al., 2001, Kamya et al., 
2002, Legros et a l ,  2002, Talisuna et al., 2002). Recently, the drug policy in 
Uganda was changed and now dictates that a combination o f CQ and SP 
(SP/CQ) be administered for treatment o f  uncomplicated P. falciparum  
malaria (Communication from the Uganda Ministry o f Health, Malaria 
Control Program, 2001). Combination therapy has been suggested to confront 
P. falciparum  resistant malaria, but the suitable combination therapy for sub- 
Saharan Africa is not yet clear. Since drug treatment is the only efficacious 
control strategy used in Uganda, monitoring o f levels o f resistance is 
important. Delaying the spread o f SP and CQ resistance is a major public 
health objective o f the Ugandan Malaria Control Programme.
1,3 Classification of in vivo resistance
Clinical drug resistance is defined according to the World Health Organisation 
(WHO) classification o f Early treatment failure (ETF), Late treatment failure 
(LTF) and Adequate clinical response (ACR). If  monitoring o f parasitaemia is 
performed, it is possible to classify resistance on three levels, known as RI, 
RII and RIII resistance (WHO, 1996; Bruce-Chwatt, 1986). The standard drug 
efficacy test is performed by the monitoring o f patients for 14 days following 
treatment. In some circumstances (especially in lower transmission areas) this 
is extended to a 28-day test.
ETF is defined as a response to chemotherapy monitored from day 1 to day 3 
post-treatment. During this period, a patient with ETF will develop signs and 
symptoms of severe malaria in the presence o f parasitaemia, or will have a 
fever and a parasitaemia on day 2 which is greater than the day 0 count, or will 
have a fever on day 3 with a parasitaemia greater or equal to 25% of the day 0 
count.
LTF is defined as a response following treatment which does not qualify for 
classification as ETF, where the patient shows signs and symptoms o f severe 
malaria in the presence o f parasitaemia, on any day from day 4 to day 14 (or to 
day 28 for the extended test) or has a fever in the presence o f parasitaemia on
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any day from day 4 to day 14 (or day 28) post-treatment.
ACR is defined as the absence o f parasitaemia throughout the follow-up 
period, with or without fever, or where there is no fever irrespective o f the 
presence o f parasitaemia, where the patient response is not classified as ETF 
or LTF.
Parasites can also be defined as sensitive or resistant at various levels by 
monitoring parasitaemia during the follow-up period. Sensitive (S) parasites 
are those that are cleared by the drug within 7 days o f treatment, and which do 
not reappear for the rest of the follow-up period. RI resistant parasites are 
initially cleared by drug treatment within 7 days, but parasites later reappear as 
a recrudescence before the end o f the study follow-up period (day 14 or day 
28). RII resistant parasites decrease initially but recrudescence occurs before 
day 7. RIII is a response with no decrease in parasitaemia; parasitaemia 
continues to increase following treatment.
In the study reported in this thesis, the treatment response pattern has been 
classified by both methods. Clinical response has been classified as ETF, LTF, 
or ACR, according to the standard WHO definitions. In addition, parasitaemia 
has been monitored, allowing the parasitological outcome o f treatment to be 
assessed as S, RI or RII/RIII.
One explanation for the different types o f resistant parasites observed is that 
RI parasites may be the result o f a low proportion o f resistant parasites in a 
mixed infection. Drug treatment would kill the sensitive parasites, thereby 
reducing the resistant parasite population to a parasitaemia below that 
detectable by mieroscopy and possibly below the threshold for symptomatic 
malaria. These resistant parasites would continue to grow in the presence o f 
the drug and eventually reach microscopically detectable parasitaemias (RI) or 
the threshold for symptomatic malaria to return (LTF). An alternative 
explanation is that resistance is not an 'all-or-nothing' response. Some parasites 
could be highly resistant and their growth would be unaffected by the
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treatment; these would be classified as RHI resistant. Other parasites could 
show slightly lower resistance, such that their growth would be initially 
inhibited by the drug, but as concentrations fall they would be able to grow 
again; these would be RII. Finally, RI parasites could be resistant to the drug 
at a lower level still, such that growth is inhibited until the drug concentration 
drops further, although this level would still be able to prevent growth of 
parasites sensitive to the drug. At present there are no studies supporting either 
hypothesis; this thesis has attempted to address the latter hypothesis.
Figure 1
Graph showing parasite resistance after treatment over a 28-day period
CO
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RIII
detection threshold
287 14 210
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There is some correlation between clinical and parasitological response, but 
generally the rate o f resistance/treatment failure is higher when measured by 
parasitaemia than by clinical response. ^
Some in vivo studies do not have a clear- cut definition o f SP clinical 
resistance, which can complicate their interpretation and comparisons with 
other data.
For example, Basco and co-workers (1998) considered ETF as RII, LTF as 
early RI and late RI as recrudescence. Masimirembwa and colleagues (1999) 
associated treatment failure with the presence o f parasites on day 2 greater 
than half o f the parasitaemia on day 0, and the presence o f parasitaemia on day
17
7 as recrudescence with the clearance o f parasitaemia by day 7 defined as 
sensitive.
In conclusion, the evidence presented in the studies discussed indicates that 
the correlation between in vitro resistance and in vivo resistance o f SP is still 
not clear, and further studies are necessary.
There is also a problem of parasite clearance by acquired immunity especially 
in more immune populations. This factor cannot be easily quantitated but can 
be hypothesised to play an important role. Individual patients may have 
different immunological capacities (independent o f resistant phenotype o f the 
parasites) to clear parasites. The level o f acquired immunity is related to both 
age (older children and adults have higher levels o f acquired immunity) and 
exposure (individuals living in areas o f high endemicity have higher levels of 
acquired immunity than those o f the same age living in areas o f lower 
endemicity) (Djimde et aL, 2001, Omar et a l, 2001). The importance of 
acquired immunity in the clearance o f drug'resistant parasites is demonstrated 
by the results o f a study earried out in Mali. Sixty-six percent (66%) o f adults 
and older children treated with chloroquine were able to clear their 
parasitaemia despite having parasites with the mutated form o f Pfcrt?6, 
whereas only 32% o f the younger children carrying the Pfcrt 76 mutant form 
were able to clear their parasitaemia (Djimde et a l, 2001). In another study 
done in a holo-endemic area in Kenya where patients were treated with SP it 
was observed that treatment suecess increased with age (Omar et a l,  2001). 
The ability to clear drug-resistant parasites increased with age, implying that 
age-acquired immunity plays an important role in the clearance o f chloroquine 
resistant parasites. Studies with the rodent model P. chabaudi showed that 
partially immune mice were able to clear drug resistant parasites more 
efficiently than naive mice (Cravo et a l,  2001).
1.4 Mechanisms of antimalarial drug resistance
The way in which parasites can acquire resistance depends on the mechanism
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by which the drug kills them. This is an important factor in determining how 
fast parasite resistance can occur.
1.4.1 Chloroquine resistance
The mechanism o f chloroquine action is not yet clear but the formation of a 
complex with haem is thought to be important (Mungithin et aL, 1998). The 
molecular basis o f drug resistance to CQ is now partially understood, although 
there is still some debate regarding the contribution o f mutations in different 
genes to resistance. Initial reports associatèd resistance with mutations in the 
gene pfmdr 1 {P. falciparum  multidrug resistance gene 1) (Foote et aL, 1989). 
Associations between pfm drl point mutations and in vivo or in vitro CQ 
resistance were inconsistent. An early study suggested that it was possible to 
predict whether an isolate was resistant or sensitive to CQ by the presence of 
defined mutations in pfm drl (Foote et aL, 1990). Studies that followed 
established an association between the presence o f a mutation at codon-86 
(causing an amino acid substitution from asparagine in the wild type to 
tyrosine in the mutant form) and in vitro CQ resistance, with sub- Saharan 
isolates (Basco et al., 1995a, Adagu et aL, 1996). A similar association was 
not observed with culture- adapted Sudanese (Awad El Kariem et aL, 1992) 
and Thai isolates (Wilson et aL, 1993). Other studies using fresh clinical 
isolates showed that the mutant allele o f pfm drl encoding tyr-86 could be used 
to predict in vivo drug resistance to CQ (Duraisingh et aL, 1997). Flowever, 
extensive field studies (Wellems et aL, 1990, Bhattacharya et aL, 1999, Adagu 
et aL, 1999, Price et aL, 1999, McCutcheon et aL, 1999, Duraisingh et aL, 
2000, Pillai et aL, 2001) produced conflicting results, casting doubts on a 
direct causal association between polymorphisms in pfm drl and CQ 
resistance. Analyses o f a genetic cross between CQ-sensitive and CQ-resistant 
parasite clones demonstrated that pfm drl mutations were not linked to the 
resistance phenotype (Wellems et aL, 1990). Transfection studies that 
followed showed that substitution o f the mutant pfm drl with the wild type 
sequence in resistant parasites decreased chloroquine resistance from high to
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moderate levels (Reed et aL, 2000). Therefore, it appears that, although 
mutations in pfm drl may not be absolutely required for chloroquine 
resistance, polymorphisms in this gene may play a role in modulating the 
resistance phenotype (Wellems et aL, 1991, Su cr aL, 1997, Reed et aL, 2000, 
Dorsey et oL, 2001).
Linkage analyses o f a genetic cross identified two loci, known as cg2 
(candidate gene 2) and Pfcrt {P. falciparum, chloroquine resistance 
transporter), implicated in chloroquine resistance (Su et aL, 1997, Fidock et 
aL, 2000b, Djimde et aL, 2001). Inheritance o f a 36 kb segment of 
chromosome 7 from the CQ resistant parent in the cross conferred resistance 
in the progeny clones. DNA sequencing and searches for open reading frames 
(ORF) encoding more than 100 amino acids within this segment identified 
nine ORF s. O f these, one ORF, denoted cg2, contained multiple and complex 
polymorphisms associated with CQ resistance both in the progeny clones of 
the genetic cross, and also in a group o f isolates from Asia and Africa (Su et 
a l,  1997). However, larger scale field studies failed to demonstrate a clear 
association between the complex polymorphisms within cg2 and CQ 
resistance (Adagu et aL, 1999, Price et aL, 1999, Durand et aL, 1999, Basco et 
aL, 1999, McCutcheon et aL, 1999, McCutcheon et aL, 2000, Pillai et aL, 
2001). Transfection-based studies confirmed that the cg2 gene was not the 
gene responsible for CQ resistance (Fidock et aL, 2000a). Extra analysis o f the 
initial 36 kb locus comprising the cg2 gene led to the discovery o f a highly 
interrupted gene, denoted Pfcrt. Polymorphisms in this gene were absolutely 
associated with CQ resistance in vitro in forty known parasite lines (Fidock et 
ciL, 2000b). A mutation in codon 76, causing an amino acid change from 
lysine (K) to threonine (T) was identified as the key mutation necessary for 
resistance. Transformation o f a CQ-sensitive P. falciparum  clone using 
plasmid constructs that expressed a Pfcrt sequence with the K76T codon 
change produced a highly CQ resistant line. However, the resistant parasites 
ended up losing the transfected DNA and instead acquired a novel mutation 
encoding K76I in the chromosomal Pfcrt gene. The change in the sequence
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directly contributed to the change in CQ phenotype (Fidock et aL, 2000b). 
There is therefore strong evidence that an amino acid change at position 76 in 
Pfcrt is associated with CQ resistance in African and Asian P. falciparum  
isolates. This is supported by field studies showing a strong link between the 
presence o f  Pfcrt? 6 mutation and clinical CQ resistance (Djimde et aL, 2001). 
Further in vivo studies on field isolates have shown that the Pfcrt ?6 mutation 
is often also present in CQ-sensitive isolates (Pillai et aL, 2001, Mayor et aL, 
2001, Dorsey et aL, 2001, Kyosiimire et aL, 2002, Chen et aL, 2002). The 
Pfcrt mutant allele is always present in CQ treatment failure samples. This 
therefore suggests that the Pfcrt 76 mutation may be necessary but is not 
always sufficient for CQ resistance in vivo.
It has been suggested that CQ resistance is a multigenic phenomenon, 
involving changes to Pfcrt and other genes such as pfindrl (Reed et aL, 2000). 
Support for this hypothesis is provided by field studies in which clinical 
treatment failure with CQ is significantly associated with parasites with the 
mutated forms o f both Pfcrt ?6 and pfm drl ,86 (Babiker et aL, 2001, Dorsey et 
aL, 2001, Mockenhaupt et aL, 2001). In addition, the relatively long time 
taken for CQ resistance to arise and spread could indicate that multiple 
mutations are required.
1.4.2 Pyrimethamine resistance
Sulfadoxine-pyrimethamine (SP)-(Fansidar) is a synergistic combination of 
drugs that interact with two enzymes o f the folate biosynthetic pathway. 
Dihydrofolate reductase (DHFRj is the biochemical target o f pyrimethamine, 
and also o f cycloguanil, the biologically active metabolite o f proguanil. In P. 
falciparum, two genes involved in the pyrimidine biosynthetic pathway, 
DPIFR and TS (thymidylate synthase) are contiguous and are expressed as a 
bifunctional enzyme DHFR-TS (Bzik et aL, 1987). Pyrimethamine binds to 
the parasite DHFR with a high affinity, inhibiting enzyme activity, resulting in 
the depletion o f dTMP and the disruption of DNA synthesis (Hyde, 1990). The
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selective activity o f pyrimethamine has usually been attributed to higher 
affinity of the drug for Plasmodium  DHFR-TS than for human DHFR 
(Hitchings, 1960; Ferone and Hitchings, 1969; Peterson et aL, 1990, Foote el 
aL, 1990). Recent work has shed light on the differential specificity o f the 
drug for parasite and human DHFR. The DHFR-TS of both species binds its 
cognate messenger RNA (mRNA) and inhibits its own translation. 
Pyrimethamine treatment removes the translational repression o f the human 
enzyme, and more DHFR is produced to partially overcome the drug barrier. 
However, in Plasmodium  DHFR-TS, mRNA binding is not coupled to enzyme 
active sites. Therefore, antifolate treatmdnt does not relieve translational 
inhibition and the parasites do not have the ability to make fresh enzyme 
(Zhang and Rathod, 2001).
Resistance to pyrimethamine is linked to a point mutation in DHFR  leading to 
an amino acid substitution at codon 108 from serine to asparagine (Peterson et 
aL, 1988, Peterson et aL, 1990). Resistance to cycloguanil has been linked to 
paired mutations in codon 16 (alanine to valine) and 108 (serine to threonine) 
(Foote et aL, 1990; Peterson et aL, 1990). Other mutations at positions 51 
(asparagine to isoleucine), 59 (cysteine to arginine) and 164 (isoleucine to 
leucine) are associated with higher levels of pyrimethamine and cycloguanil 
resistance (Foote et aL, 1990, Peterson et aL, 1990).
Following the introduction of pyrimethaniine monotherapy, resistance was 
reported within a year (Maberti, 1960), most likely as a result o f  the simple 
resistance mechanism. Pyrimethamine is now used only in synergistic 
combinations with sulfadoxine or other antifolates (Chulay et aL, 1984), so it 
is not possible to correlate in vivo pyrimethamine treatment failure with DHFR 
genotype. However parasites taken from infected individuals can be tested for 
their pyrimethamine susceptibility in vitro. In these tests, resistance is denoted 
by an IC50 value o f > 100 nM (de Pé cou las et aL, 1996). Such studies reveal a 
very strong link between mutations in DHFR  and pyrimethamine and 
cycloguanil resistance. For pyrimethamine, DHFR AsnlOS is almost 
completely associated with resistance to pyrimethamine, and the presence of
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parasites encoding DHFR S eri08 alone is a good indicator o f sensitivity in 
vitro to pyrimethamine (e.g. de Pécoulas et al., 1996, Basco et al., 1995b, 
Basco et al., 1996, Foote et al., 1990, Flyde et a l,  1990, Khan et al:, 1997, 
Peterson et al, 1990, Reeder et al., 1996 and Zindrou et al., 1996). Geometric 
mean 50% inhibitory concentration values (IC50) were over 1000-fold higher 
for parasites with DHFR  AsnlOS from African patients compared to parasites 
with DHFR S e ri08 (IC50 o f 4050 nM for Asn 108 and 12.5 nM for Ser 108). 
The central mutation implicated in pyrimethamine resistance is at position 108 
(Cowman et a l ,  1988, Peterson et al., 1988, Zolg et ah, 1990), a finding that 
was confirmed by transfection studies (Wu et al., 1996). It is believed that 
additional mutations in DHFR codons 51 and 59, combined with the AsnlOS 
change, confer higher levels o f resistance. Kinetic analysis o f the P. 
falciparum  DFIFR-TS enzyme after expression in Escherichia coli confirmed 
the role o f these mutations in the different levels o f resistance. The inhibition 
constant (Kj) values for the double mutants Asnl08/Arg59 and Asnl08/Ile51 
are 72 nM and 37 nM respectively, compared to 13 nM for the single mutated 
allele encoding AsnlOS (Sirawaraporn et a i ,  1997). The inhibition constant 
for parasites carrying the triple mutant AsnlOS/ IIe51/ Arg59 was 120 nM 
(Sirawaraporn et a l, 1997) indicating a much higher level o f resistance as 
compared to the single and double mutated alleles.
Transfection experiments have also been performed using DHFR as a 
selectable marker that confers resistance to pyrimethamine (Wu et al., 1996). 
Pyrimethamine-sensitive parasites transformed with the DHFR allele from 
parasite Dd2 (triple mutant form o f  DHFR Asnl08/Ile51/Arg59) yielded drug- 
resistant parasites with an IC50 o f 16 nM. Transformation with the DHFR  gene 
from parasite FIB3 (single mutant form AsnlOS) yielded parasites with an IC50 
value o f 1.0 nM. Investigating the effect of the additional mutation in DHFR 
at codon 51 was also done by transfection o f P. falciparum  DHFR alleles into 
yeast (Wooden et al., 1997). This suggests that the double mutant form DHFR 
Asnl08/lle51 (pf-dhfr-M\k.QngSL, a resistant construct) causes a further ten-fold
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increase in IC50 compared to the single mutant form DHFR AsnlOS {pf~dhfi^~ 
Honduras, a resistant construct), which itself produces a ten-fold increase in 
IC50 compared to the wild type form DHFR Ser 108 (pf-dhfr-D6, a sensitive 
construct).
However it is difficult to predict what the effects of these mutations may be on 
in vivo treatment failure. In vitro studies usually describe IC50 values, which is 
the lowest inhibitory concentration of the drug which kills 50% of the 
parasites. This implies that 50% o f the parasites remain viable. In vivo this is 
most likely to result in treatment failure.
1.4.3 Sidfadoxine resistance
Sulfadoxine, the other component o f the combination drug SP, is also never 
used as monotherapy for malaria. The information on the resistance 
mechanisms to sulfadoxine alone has therefore been obtained from in vitro 
work. The molecular target o f sulfadoxine is the enzyme DHPS, a part of a 
bifunctional protein with hydroxymethylpterin pyrophosphate. Sulfadoxine is 
a structural homologue o f 4-amino benzoic.acid (PABA) the natural substrate 
o f DHPS (Brooks et a l,  1994, Triglia and Cowman, 1994) and is a 
competitive inhibitor o f the enzyme. Mutations in the DHPS gene are found in 
natural populations, and have been correlated with resistance to SP in vivo, for 
example, mutations leading to amino acid changes at positions 437 (alanine to 
glycine), 436 (serine to phenylalanine), 613 (alanine to serine), and 581 
(alanine to glycine) (Triglia et al., 1997, Plowe et al., 1997, Wang et al., 
1997a).
Some studies have attempted to correlate in vitro sulfadoxine resistance and 
DHPS mutations with isolates taken from the field and with laboratory lines, 
but these have not been conclusive (Table T. a, b, d, and f). In vitro assays for 
sulfadoxine have been done under varying folate conditions (Wang et a l, 
1997b), and some parasite isolates are known to use host folate to antagonise
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sulfa drugs irrespective o f their DHPS genotype (Milhous et a l ,  1985, 
Watkins et a l ,  1985). Sulfadoxine in v/Yz^o-drug testing is technically difficult 
but can be done using culture medium depleted o f folate and PABA that 
antagonise sulfadoxine (Chulay et a l,  1984, Watkins et al., 1985, Milhous et 
al,, 1985). Published data for IC50 (50% Inhibitory concentration) values show 
very large differences, varying from 10 nM (Milhous et al., 1985) to 150 nM 
(Watkins et al., 1987), or from 1000 nM (Chulay et al., 1984) to as high as 3 
X 10  ^ nM (Schapira et ah, 1986) for sulfadoxine- sensitive strains. Relatively 
small differences in IC50 are observed between parasites classified as resistant 
or sensitive to sulfadoxine.
A direct correlation between DHPS point inutations and in vitro sulfadoxine 
resistance was demonstrated using the progeny of a cross between the 
sulfadoxine- sensitive parasite clone HB3 and the sulfadoxine-resistant clone 
Dd2 (Wang et a l ,  1997b). Consistently reproducible results showing large 
differences between the most sensitive and most resistant progeny clones were 
obtained as a result o f using an improved drug assay in the absence o f folate. 
Differences in sulfadoxine responses o f the individual progeny from the PIB3- 
Dd2 cross were monitored. Parental clone HB3 with a 'wild type' (unmutated) 
allele o f DHPS  had the lowest IC50 value o f 12.9 nM. Progeny clones 
inheriting the DHPS allele from this parent had IC50 values in the same range. 
The Dd2 parent clone carrying the three DHPS  mutations 436 Phe/437 
Gly/613 Ser showed the highest IC50 value o f 12.8 X 10  ^ nM, 1000-fold 
higher, as did progeny clones inheriting the Dd2 allele.
Site directed mutagenesis studies involving alterations in the amino acids in 
the DHPS enzyme yielded alleles with varying inhibition constants for 
sulfadoxine (Triglia et al., 1997). Eight plasmid constructs were made that 
expressed the alleles o f the functional P. falciparum DHPS in Escherichia 
coli. After purification, the inhibitory constant for sulfadoxine was measured 
for the eight DHPS enzymes by a competitive mechanism. The Kj for 
sulfadoxine for all the eight enzymes varied significantly by up to 811-fold (3
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orders o f magnitude). Enzyme DIO-C (with a sequence identical to P. 
falciparum  3D7) present in sulfadoxine-sensitive isolates had the lowest Kj 
value of 1.4 X 10  ^nM and W2 mef-C, which is present in highly sulfadoxine- 
resistant isolates, had the highest Kj value o f 11.2 X lO'^  nM.
Another mechanism associated with folate uptake and utilisation is thought to 
have an effect on the sulfadoxine resistance levels (Wang et al., 1999). Low 
levels o f folate in the culture medium can result in a reduction in the 
susceptibility o f the parasites to sulfadoxine (known as the folate effect). 
Parasite clone Dd2 had markedly lower IC50 values under low folate 
conditions, whereas clone HB3 showed little or no change in the IC50 values 
observed compared with those obtained in normal medium. The difference 
between the two clones was suggested to be due to another gene that strongly 
influences resistance o f a specific clone to sulfadoxine depending on the levels 
o f exogenous folate.
1.4.4 SP  resistance
The association o f mutations in both DHFR and DHPS with resistance to SP 
in malaria parasites has been investigated (Hyde et al., 1990, Brooks et al.,
1994). Previous studies have analysed the correlation between in vitro 
sulfadoxine resistance and DHPS genotype separately from in vitro 
pyrimethamine resistance and DHFR genotype. Generally, laboratory adapted 
strains o f P. falciparum  have been used, although field isolates have also been 
studied occasionally. It is not clear what role point mutations in the DHFR  and 
DHPS genes play in in vivo pyrimethamine and sulfadoxine resistance, as 
these drugs are never used alone (Hyde, 1990, Wang et a l ,  1997a). Although 
an in vitro SP susceptibility test has been described, the 'folate effect' 
described above can complicate their interpretation, and most studies have 
used samples from clinical SP treatment failure. The molecular criteria for in 
vitro antifolate resistance have not been confirmed or correlated with in vivo 
response o f patients treated with SP (Rallon et a l,  1999). Furthermore, the
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DHFR and DHPS allelic combinations that may be associated with SP 
therapeutic failure are not yet clearly known.
Controversies have arisen between different studies showing evidence for and 
against mutations in DHFR  and DHPS  being implicated in SP resistance o f P. 
falciparum  strains, and these will be described below. Studies dealing with the 
determination o f genetic changes as the basis o f clinical resistance have been 
carried out in West Africa (Plowe et a / . , , 1995; 1996). These studies have 
confirmed that the molecular diagnostic techniques used are appropriate for 
epidemiological studies o f resistance where it is not possible using standard in 
vitro and in vivo methods for detecting resistance. They also show that 
surveillance studies carried out at intervals to determine resistance levels in 
different regions using these molecular assays may assist health officials in 
changing antimalarial drug treatment policies accordingly. Arguments have 
been made for limiting the distribution and the use o f specific antimalarial 
drugs, but evidence that such an approach can slow down the spread of 
resistance has been lacking (Price and Nosten, 2001).
Evidence for or against the role of DHJFR and DHPS mutations in SP 
resistance in vivo and in vitro
Several studies have been carried out to investigate the role o f mutations in 
DHFR and DHPS in clinical SP resistance. Field tests carried out in Kenya 
both in vivo and in vitro have suggested that pyrimethamine resistance alone 
(associated with mutations in DHFR) is sufficient to cause SP failure 
(Nguyen-Dinh et a l,  1982). This was supported by a study done in Tanzania, 
which showed evidence o f in vivo selection under SP drug pressure of 
parasites with alleles encoding the DHFR Asparagine 108 mutant (Curtis et 
a l,  1996). An in vivo study carried out in Mali showed that SP selected for 
DHFR mutants rapidly, with Arginine 59 (55.0%) and Asparagine 108 
(55.0%) being more common in post-treatment isolates, supporting their role 
in SP failure (Diourte et a l, 1999). However, because there was a low level of
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in vivo SP resistance in the study area, it was not possible to identify any
'I
group of DHFR  or DHPS mutations that were predictive o f elinieal SP failure. 
A study carried out in Cameroon showed that the triple DHFR  mutant 
encoding Asn 108/Arg 59/1 le 51 was strongly associated with in vivo 
resistance to SP (Basco etal., 2000).
There is also evidence that mutations in both DHFR and DHPS  are necessary 
for in vivo SP resistance. Studies carried out in West and East Africa, the 
Middle East and Vietnam (Wang et ah, 1997a, Schapira et a l, 1986) suggest 
that DHFR 108 and DHPS 437 changes are necessary for SP treatment failure. 
The study by Schapira also performed in vitro sulfadoxine tests on parasites 
from SP-resistant cases and found that the in vitro results reflected the in vivo 
treatment failure. A study carried out in Peru (Kiiblin et al., 1998) showed that 
a collection o f mutations in DHFR (Asn 108/lle 51/Leu 164) and DHPS (Gly 
437/Glu 540/Gly 581) was strongly associated with in vivo SP resistance. In 
Vietnam, a combination of multiple DHFR  antifolate resistance mutations 
coupled with the 437 Glycine mutation in DHPS correlated best (72%) with in 
vivo resistance to SP (Masimirembwa et al., 1999). In Kenya, a combination 
o f the triple DHFR  mutant (Asn 108/Ile 51/ Arg 59) coupled with the DHPS 
double mutant (Gly 437/Glu 540) was associated (55.2%) with in vivo 
resistance to SP (Nzila et al., 2000).
In other studies, however, mutations in DHFR and DHPS were not 
informative for predicting SP resistance. A study done in Colombia showed 
that DHFR alleles encoding Asn 108 were detected in 75% of clinical samples 
with adequate clinical response (ACR) and in all the treatment failure samples, 
rendering it inadequate for predicting SP treatment failure (Rallon et a l, 
1999). Studies carried out in Tanzania found no association between the 
presence o f mutations at different loci o f the DHFR gene before treatment and 
subsequent clinical SP resistance (Jelinek et al., 1997).
It has also been argued that DHPS mutations do not play a role in SP failure
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(Watkins et al., 1997). A study carried out in Mali found no significant 
selection by SP for DHPS mutations, including no significant selection against 
the DPIPS allele encoding Ala-436 (Diourte et al., 1999). In Vietnam, only 
two out o f seven samples resistant to SP in vivo were fully explained by the 
known DHPS mutations as investigated by mutation-specific PCR 
(Masimirembwa et al., 1999). A study carried out in Cameroon to assess SP 
efficacy showed there was no effect on clinical outcome by the DHPS 
genotype (Basco et al., 2000). From these studies and those listed in Tables 1 
and 2, it is difficult to judge whether molecular changes in the DHFR  and/or 
DHPS correlate with in vivo treatment failure with SP. Tables 1 and 2 
summarise some o f  the studies performed to investigate the association 
between DHFRJDHPS mutations and SP resistance.
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Table 1
DHFR/DHPS mutations and SP resistance in vitro 
The listed references provide evidence o f a correlation between 
mutations in DHFR  and DHPS and resistance to pyrimethamine and 
sulfadoxine respectively
Evidence supporting the role of Asn-108 
and other DHFR mutant codons in 
pyrimethamine in-vitro resistance
Evidence supporting the role of Gly-437 
and other DHPS mutant codons in 
sulfadoxine in-vitro resistance
1. Basco et a l, 1996 
Exp. Parasitoi. 82:97-103
a. Basco et a l, 1998a 
Am. J. Trop. Med. Hyg. 58: 374-378
2. Basco et al., 1995 
Mol. Biochem. Parasitoi. 69: 135-138
b. Brooks et a l, 1994 
Bur. J. Biochem. 2: 397-405
3. Foote et a l, 1990 
Proc. Natl. Acad. Sci. USA. 87: 3014-3017
c. Reeder e ta l, 1996 
Am. J. Trop. Med. Hyg. 55: 209-213
4. Hyde etal., 1990 
Pharmacol. Ther. 48: 45-49
d. Triglia e ta l, 1994 
Proc. Natl. Acad. Sci. USA 91: 7149-7153
5. Khan etal., 1997 
Trans. R. Soc. Trop. Med. Hyg. 91: 456- 
460
e. Triglia era/., 1997 
Proc. Natl. Acad. Sci. USA. 94: 13944- 
13949
6. Nzila-Mounda et a l, 1998 
Antimicrob. Agents Chemother. 42: 164- 
169
f. Wang era/., 1995 
Mol. Biochem. Parasitoi. 71: 115-125
7. Peterson et al., 1990
Proc. Natl. Acad. Sci. USA. 87: 3018-3022
g. Wang e ta l, 1997b
Mol. Microbiol. 23; 979-986
8. Reeder et al., 1996 
Am. J. Trop. Med. Hyg. 55: 209-213
h. Triglia et a l, 1998 
EMBO J. 17: 3807-3815
9. Zindrou et a l, 1996 
Exp. Parasitoi. 84: 56-64
10. Zolg e? a/., 1989
Mol. Biochem. Parasitoi. 36: 253-262
11. Cowman et al., 1998
Proc. Natl. Acad. Sci. USA. 85: 9109- 
9113
12. Peterson et al., 1998
Proc. Natl. Acad. Sci. USA. 85: 9114- 
9118
13, Basco et a l, 1998b
Antimicrob. Agents Chemother. 42: 1811- 
1814
14. Wilson et a l, 1993
Mol. Biochem. Parasitoi. 57: 151-160
15. Awad-El-Kariem e /«/., 1992
Trans. R. Soc. Trop. Med. Hyg. 52 (6): 
565-568
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1.5 Hypothesis:
The hypothesis being tested is that early treatment failure is caused by 
parasites with several mutations in DHFR. i.e. a higher level o f resistance, as 
indicated by more mutated codons in DHFR, is predicted in parasites causing 
early treatment failure than in parasites causing late treatment failure.
Molecular techniques to monitor drug resistance are dependent on polymerase 
chain reaction (PCR)-based methods to amplify genes associated with drug 
resistance (Plowe et a!., 1995). Mutation-specific PCR techniques are able to 
indicate the presence o f parasites within a sample carrying alleles o f the gene 
under investigation which are associated with resistance or sensitivity to the 
drug. However the sensitivity and specificity o f these techniques may be 
compromised by the multiplicity o f P. falciparum  genotypes in natural 
infections (Ranford-Cartwright et a l, 2002). A PCR/dot-blot hybridisation 
technique for detecting point mutations at residues 108, 51 and 59 o f the P. 
falciparum DHFR  gene, which are associated with pyrimethamine resistance, 
has recently been developed (Abdel-Muhsin et a l, 2002). The technique 
combines PCR amplification and hybridisation o f amplified products using 
radiolabelled allele-specific oligonucleotide probes. The dot-blot method was 
as sensitive as the mutation-specific PCR technique, and was more specific in 
a series of comparisons (Ranford-Cartwright et a l, 2002). Characterisation of 
parasite genes was possible from samples with a parasitaemia as low as 100 
parasites/pl o f blood. It was also possible to identify a minority parasite 
genotype down to 1% in a mixture. The dot-blot technique is more suited to 
high throughput studies, because each dot-blot can contain PCR products from 
over 90 samples.
In this study, mutation-specific PCR has been used to type alleles o f Pfcrt 
codon 76, because the dot-blot method had not yet been developed for this 
locus. The PCR/dot-blot hybridisation technique was applied to detect alleles 
of DHFR associated with drug resistance in parasites with recrudescent
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infections. The patient samples were collected during an in vivo drug efficacy 
study o f SP and the combination o f SP and CQ, carried out in Uganda.
The results from the typing were used to investigate if mutations in the DHFR 
gene in P. falciparum  pre-treatment isolates are predictive o f failure o f SP/CQ 
and SP treatment during follow-up. In addition, we investigated if the number 
of mutations in DHFR  was correlated with time to recrudescence, i.e. does the 
number o f days to recrudescence correlate with more DHFR mutations in the 
resistant parasites at the time the drug was given?
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2. MATERIALS AND METHODS:
2.1. Study area and population
The study was carried out during the period December 2001-March 2002 in 
Nagongera Health Centre in Tororo district, Eastern Uganda, one o f the 
sentinel sites chosen by the East Africa Network for Monitoring Antimalarial 
Treatment (EANMAT) and the Uganda National Malaria Control Programme 
(UNMCP) for surveillance o f antimalarial drug efficacy. A clinical drug 
efficacy trial was performed to compare the efficacy of SP and a combination 
o f Chloroquine and SP in symptomatic children with uncomplicated 
falciparum  malaria.
Tororo District lies at an altitude approximately between 1,097 m and 1,219 in 
above sea level and has a population o f approximately 400,000. It borders the 
Republic o f Kenya to the East, and has the Ugandan districts Mbale to the 
North East, Iganga to the West, Busia to the South and Pallisa to the North. 
Tororo District has a bimodal rainfall pattern with peak rainfall during the 
months o f March to May and August to September and high temperatures 
most o f the year. The area is holo-endemic for malaria, registering an average 
of 4500 malaria cases monthly (Epidemiological Surveillance Division, 
Ugandan Ministry o f Health). The parasite prevalence in children aged 2-9 
years is 88% (Talisuna et a l,  2002). The main occupation o f the population 
(the Japadhola, the Banyole and the Iteso) in this rural region is subsistence 
agriculture.
Children aged between 6 months and 5 years old were enrolled into a drug 
efficacy trial according to the EANMAT field manual and the standard World 
Health Organisation (WHO) protocol for areas o f intense transmission (WHO 
1996), but adapting the trial to a 28-day test and not the standard 14-day test. 
Inclusion criteria were: uncomplicated malaria, with P. falciparum
monoinfection, axillary temperature > 37.5“C or history o f fever in the past 24 
hours, and an asexual parasitaemia between 2000 parasites per pi blood and
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Ethical approval for the study was obtained from the Uganda National Council 
o f Science and Technology (UNCST) and the Institutional Review Board 
(IRB) of the University o f Glasgow, UK.
100,000 parasites per pi o f blood. The children were recruited with informed 
consent from their parents or guardians, treated and followed up to day 28 
after treatment. Active recrudescent case detection was initiated at the point o f 
enrolment into the study, when parents or guardians were asked to return the 
children after treatment on appointment i.e. day 3, 7, 14, 21 and 28, 
irrespective o f their clinical status at that time. Passive recrudescent case 
detection was done at any time during follow-up. Any child who felt ill within 
the 28 days after initial treatment was requested to return to the clinic for 
resampling and retreatment with an alternative drug where appropriate. 
Children who presented with or subsequently developed severe malaria 
symptoms or other causes o f fever, those with severe malnutrition and those 
with a history o f allergic reactions to sulfa drugs were not recruited to the trial. 
Children who did not complete the follow up, those who took antimalarial 
drugs from other sources, and those who developed complications were not 
considered in the analysis as per the protocol.
2.2. Sample collection, treatment and follow-up
One hundred eighty one (181) children were recruited to the trial. A fmger- 
prick blood sample was taken at admission to the trial. Thin and thick smears 
were prepared and stained with Giemsa's stain for the assessment of 
parasitaemia on the first day o f treatment (known as DO) and on each day of 
subsequent visits. A fmger-prick sample o f blood from each study subject was 
also taken onto filter paper (3MM Whatman) for later molecular studies 
(polymerase chain reaction (PCR) analysis) at each sampling point. The filter 
papers were air dried at room temperature and placed into individual self- 
sealing plastic bags and stored at room temperature.
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The recruited children were followed up on days 1, 2, 3, 7, 14, 21 and 28, 
and/or on any day that they developed symptoms. On entry to the trial, 
children were treated with either a combination o f CQ (150mg base) and SP 
(500mg S + 25mg P), or with SP alone (500mg S + 25mg P), administered 
orally under the direct supervision o f a study nurse. The two trials were done 
simultaneously. The first recruited child was assigned to the SP/CQ treatment 
group and the second child to the SP treatment group. That same order was 
followed for all the other recruited children. For CQ, the drug was given over 
3 days. The total CQ given was calculated according to body weight at 25mg 
CQ per kg body weight o f the child. This was divided into three doses o f 10 
mg/kg on day 0 and day 1, and 5 mg/kg on day 2). The drugs were all quality 
assured. Beginning on day 3, follow up was stopped after confirming the
:
presence o f malaria parasites in the blood (>25% of DO parasite count) o f a
'
child. This was termed as a recrudescent sample to await confirmation by 
PCR. At this point the child was treated with an alternative drug as advised by 
the treating clinician, and took no further part in the study beyond the 
treatment failure sampling at that time.
2.3. Definition of outcomes
Clinical outcome was defined as described earlier according to the WHO 
classification o f adequate clinical response (ACR), early treatment failure 
(ETF), and late treatment failure (LTF) (WHO, 1996). Parasitological 
response was defined using the standard sensitive (S), resistance level 1 (Rl), 
resistance level 11 (Rll), and resistance level 111 (RIB) classification system 
(Bruce-Chwatt, 1986).
2.4. Slide exam ination
Thin films were fixed with methanol and both thin and thick films were 
stained with 10% Giemsa's stain for 30 minutes. The number o f asexual
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p. falciparum  parasites per 200 white blood cells (WBC) was counted under 
100 times (high power) magnification oil immersion fields. The number o f 
parasites was multiplied by 40 to calculate the parasite density per micro litre 
of blood. This assumes a WBC count o f 8000/pl (WHO, 1991). Where less 
than 10 parasites per 200 WBC were found, the count was continued to 500 
WBC and the parasite count determined correspondingly. A sample was 
declared negative after examining 200 thick film fields without observing any 
asexual parasites.
2.5. DNA extraction, PCR amplification and product analysis
Extraction and purification o f parasite DNA from blood samples on filter 
paper was performed using the Chelex-100 method as described (Plowe et a l,
1995). All o f the blood from a single spot was used and the final volume o f 
DNA solution obtained was approximately 200pl. Extracted DNA was used 
immediately or stored at -80°C for later PCR amplification o f DNA.
2.5.1. Genotyping at the Pfcrt locus
Mutations in P. falciparum  chloroquine resistance transporter gene {Pfcrt), 
specifically those causing an amino acid substitution from lysine to threonine 
at position 76 (K76T), were detected by mutation-specific polymerase chain 
reaction (MS-PCR) (Djimde et a l,  2001). In the first round PCR, 
oligonucleotide primer pairs TCRPl (5’-CCG TTA ATA ATA AAT ACA 
CGC AG-3’) and TCRP2 (5’-CGG ATG TTA CAA AAC TAT AGT TAG C- 
3’) were included in a single reaction. Five microlitres o f genomic DNA was 
used as template in the primary reaction. The reaction took place in a total 
volume of 25 pi containing 20 niM Tris-Cl pH 8.4, 50 mM KCl, 2,5 mM 
MgCE, 200 pM of each dNTP (dGTP, dATP, dTTP, dCTP), primers at a final 
concentration o f 0.1 pM each and 0.625 units o f Taq DNA polymerase (Roche 
Diagnostics, Mannheim, Germany). The amplification program for Pfcrt was 
as follows: dénaturation for 30 seconds at 94°C, annealing for 30 seconds at
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56°C, extension for 1 minute at 60°C. Forty-five cycles were performed for 
the primary reaction. The last extension was carried out for 3 minutes at 60°C. 
Ten micro litres o f primary PCR product were mixed with 1-2 pi o f lOX 
loading dye (0.25% bromophenol blue, 0.25% xylene cyanol, 25% ficoll (type 
400) in water) and analysed by agarose gef electrophoresis on a 1.5% agarose 
gel stained with ethidium bromide (0.8 pg /mi) in Tris-acetate-EDTA buffer.
A primary PCR product present as a strong DNA band on the agarose gel was 
diluted 1:100 with DNase and RNase-free water (ICN Biomedicals, Inc., 
Irvine, CA, USA) before use as template in the nested reaction. A primary 
PCR product present as a faint band following electrophoresis was diluted 
1:10 before use. A PCR product with no band visible on the gel was used 
undiluted in the nested PCR.
The PCR product generated from the primary reaction was used as template in 
the nested PCR. Two separate reaction mixes were prepared, one containing 
primers specific to the wild type allele encoding Pfcrt Lys76, and the other to 
the mutant form encoding Pfcrt Thr76. Thè primers used were TCRP4w (5’- 
GTT CTT TTA GCA AAA ATC T-3’) for the wild type allele or TCRP4m 
(5’-GTT CTT TTA GCA AAA ATT G-3’) for the mutant allele. Each specific 
primer was paired with the common primer TCRP3 (5’-TGA CGA GCG TTA 
TAG AG-3’). One microlitre o f the neat or Ipl of the diluted primary PCR 
product was used as template in the nested PCR reaction. The reaction was 
performed in a total volume o f 25pi containing 20mM Tris-Cl pH 8.4, 50 mM 
KCl, 1.5 mM M gCb, 200 pM o f each dNTP (dGTP, dATP, dTTP, dCTP), 
primers at a final concentration of 1 pM each and 0.625 units o f Taq DNA 
polymerase. The amplification program for Pfcrt76 was as follows: 
dénaturation for 30 seconds at 94°C, annealing for 30 seconds at 47°C, 
extension for 1 minute at 64°C. Fifteen cycles were performed for the nested 
reaction. Twenty micro litres o f the nested PCR product were mixed with 1-2 
pi o f lOX loading dye (0.25% bromophenol blue, 0.25% xylene cyanol, 25% 
ficoll (type 400) in water) and analysed by agarose gel electrophoresis on a
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1.8% agarose gel stained with ethidium bromide (0.8 pg/ml) in Tris-acetate- 
EDTA buffer. For each day 0 (DO) sample, the two amplification reactions 
(specific amplification of the wild type and mutant alleles of Pfcrt) were run 
side-by-side on the agarose gel. The same was done for the day of 
recrudescence (R) PCR products as shown in Figure 2.
Figure 2:
A schematic to indicate loading of gels for Pfcrt analysis 
Day 0 R
1 2  1 2
Lane 1 shows PCR product band after amplification of DNA with Pfcrt wild 
type primer
Lane 2 shows PCR product band after amplification of DNA with Pfcrt mutant 
primer
DNA was visualised by ultraviolet transillumination and the band sizes 
determined by comparison with a standard size 100-base pair DNA ladder 
(Roche Diagnostics, Mannheim, Germany). P. falciparum DNA clones 3D7 
and FCB-1 were included in each run as controls for the wild type and mutant 
alleles, respectively.
2.5.2. Distinguishing recrudescent from new P. falciparum infections 
To distinguish genuine recrudescence of resistant parasites from the 
appearance of parasites arising from reinfection during the follow-up period, 
day 0 (pre-treatment) and the day of recrudescence-R (post-treatment) isolates 
were genotyped at two highly polymorphic gene loci, merozoite surface 
protein-1 (MSPJ) and merozoite surface protein-2 {MSP2), as described 
(Ranford-Cartwright et al., 1993).
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2.5.2.1, Genotyping at the MSPl locus
In a primary PCR, oligonucleotide primer pairs 01 (5’-CAC ATG AAA GTT 
ATC AAG AAC TTG TC-3’) and 02 (5’-GTA CGT CTA ATT CAT TTG 
CAC G-3’), corresponding to the conserved sequence on either side o f the 
repetitive region o f M SPl (block 2), were included in a single reaction. Using 
the PCR product generated from the primary reaction as template, the 
polymorphic repetitive region o f block 2 o f MSP I  was amplified in a nested 
PCR. Specific primers N1 (5’-GCA GTA TTG ACA GGT TAT GG-3’) and 
N2 (5’-GAT TGA AAG GTA TTT GAC-3’) were used.
Amplifications were performed using a PTC-100™ PCR System (MJ 
Research, Inc., Waltham, MA, USA). In the primary and nested M SPl PCR 
amplification, the reaction took place in total volume of 25 pi containing 10 
mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgClz, 75 pM  of each dNTP 
(dGTP, dATP, dTTP, dCTP), primers at a final concentration o f 0.1 pM each 
and 0.5 units o f Taq DNA Polymerase (Roche Diagnostics, Mannheim, 
Germany). Five micro litres o f parasite DNA was used as template in the 
primary reaction, and 2 pi o f the primary PCR product was used as template in 
the nested PCR reaction. The amplification program for M SPl was identical 
for both reactions: dénaturation for 25 seconds at 94°C, annealing for 35 
seconds at 50°C, extension for 2 minutes 30 seconds at 68°C. Thirty cycles 
were performed for both primary and nested reactions. The final extension was 
carried out for 8 minutes at 68°C. Ten micro litres (or 15 pi for nested PCR 
product) o f primary PCR product were mixed with a 1-2 pi o f lOX loading 
dye and analysed by agarose gel electrophoresis on a 1.5% (or 2.0% for nested 
PCR products) agarose gel stained with ethidium bromide (0.8 pg/ml) in Tris- 
acetate-EDTA buffer. Each day 0 (DO) isolate was run alongside its day of 
recrudescence (R) isolate. DNA was visualised by ultraviolet transillumination 
and band sizes determined by comparison with a standard 100-base pair DNA 
ladder.
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2.5.2.2. Genotyping at the M SP2 locus
Oligonucleotide primer pairs S2 (5’-GAG GGA TGT TGC TGC TCC ACA 
G-3’) and S3 (5’-GAA GGT AAT TAA AAC ATT GTC-3’) corresponding to 
the conserved sequence surrounding the central repetitive and polymorphic 
regions o f MSP2 were included in a single reaction. Using the PCR product 
generated from the primary reaction as template, the polymorphic repetitive 
regions of block 2 and 3 o f MSP2 were amplified by a nested PCR. In this 
case, specific primers SI (5’-GAG TAT AAG GAG AAG TAT G-3’) and 84 
(5’-CTA GAA CCA TGC ATA TGT CC-3’) were used. Amplifications were 
performed using a PTC-100™ PCR System. In the primary and nested MSP2 
PCR amplification, the reaction took place in a total volume of 25 pi 
containing 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 niM M gCb, 75 pM of 
each dNTP (dGTP, dATP, dTTP, dCTP), primers at a final concentration of 
0.1 pM each and 0.5 units o f Taq DNA Polymerase. Five micro litres of 
parasite DNA was used as template in the primary reaction, and 2 pi of the 
primary PCR product was used as template in the nested PCR reaction. The 
amplification program for MSP2 was as follows: dénaturation for 25 seconds 
at 94°C, annealing for 60 seconds at 42°C (or 60 seconds at 50°C with nested 
reaction), extension for 2 minutes at 65°C (or 60 seconds at 70°C with nested 
reaction). Thirty cycles were performed for both primary and nested reactions. 
The final extension was carried out for 8 minutes at 65°C (or 8 minutes at 
70°C in the nested reaction). Ten microlitres (or 15 pi for nested PCR product) 
o f primary PCR product were mixed with a 1-2 pi o f lOX loading dye and 
analysed by agarose gel electrophoresis on a 1.5% (or 2.0% for nested PCR 
products) agarose gel stained with ethidium bromide in Tris-acetate-EDTA 
bu ffer. Each day 0 (DO) isolate was run alongside its day o f recrudescence (R) 
isolate. DNA was visualised by ultraviolet transillumination and band sizes 
determined by comparison with a standard 100-base pair DNA ladder. Three 
categories o f recrudescent infections were identified: (i) genuine recrudescent
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infections, (ii) infections with evidence o f recrudescent and also o f new 
infections and (iii) entirely new infections.
2.6. Polymerase chain reaction and dot-blot at the DHFR locus
Oligonucleotide primer pairs AM Pl (5’-TTT ATA TTT TCT CCT TTT TA- 
3 ’) and AMP2 (5’-CAT TTT ATT ATT CGT TTT CT-3’) were included in a 
single outer PCR reaction. Using the PCR product generated from the primary 
reaction as template, a nested PCR was then carried out using primers based 
on conserved sequences, so that the PCR product would include codons 108, 
51 and 59 in DHFR. SPl (5’-ATG ATG GÀA CAA GTC TGC GAC-3’) and 
SP2 (5’-ACA TTT TAT TAT TCG TTT TC-3’) were the nested primers used 
(Plowe et a i, 1995). Control amplifications, using DNA from P. falciparum  
parasite clones known to contain the possible different alleles at positions 108, 
51 and 59 o f DHFR, were used to ensure specificity and sensitivity o f the 
technique (Table 3).
2.6.1. AMP1/AMP2 PCR amplification
Amplifications were performed using a PTC-200™ PCR System (MJ 
Research, Inc., Waltham, MA, USA). In the primary PCR amplification, the 
reaction took place in a total volume of 20 pi containing 10 mM Tris-HCl pH
8.3, 50 mM KCl, 1.5 mM M gCh, 200 pM o f each dNTP (dGTP, dATP, dTTP, 
dCTP), primers at a final concentration o f 0.1 pM each and 1 unit o f Taq DNA 
Polymerase. Five microlitres of parasite DNA was used as template in the 
primary reaction. Two micro litres o f DNA extracted from in vitro cultures of 
P.falciparum clones 3D7 and Dd2, which have DHFR  encoding Asn and lie 
respectively at position 51, Cys and Arg respectively at position 59, and Ser 
and Asn respectively at position 108, were used as the major positive controls 
(Table 3). P. falciparum  clones HB3 and V l/S  were used as alternative 
controls. P. falciparum  clone T9-94 which has DHFR encoding Thr at position 
108 was not used because the mutant form encoding DHFR Thr 108 is rare in
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Africa (Plowe et al., 1997, Nzila-Mounda et al,, 1998).
Table 3
Positive and negative conti'ol parasite clones for the DHFR locus
Parasite
Clone
DHFR
Codon 108 Codon 51 Codon 59
Ser (W) Asn (M) Thr (M) Asn (W) lie (M) Cys (W) Arg (M)
3D7 positive negative negative positive negative positive negative
Dd2 negative positive negative negative positive negative positive
HB3 negative positive negative positive negative positive negative
Vl/S negative negative negative negative positive negative positive
W= wild type, M= mutant 
Controls labelled in bold were the major ones used for the experiments.
The amplification program for AMP1/AMP2 PCR was as follows: 
dénaturation for 30 seconds at 92°C, annealing for 45 seconds at 45°C, 
extension for 45 seconds at 72°C for forty five cycles. The last extension was 
carried out for 3 minutes at 72°C.
2.6,2. SP1/SP2 PCR amplification
In the nested PCR amplification, the reaction took place in total volume o f 30 
pi containing 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCla, 200 pM 
of each dNTP (dGTP, dATP, dTTP, dCTP), primers at a final concentration of 
1 pM each and 1 unit o f Taq DNA Polymerase. Two micro litres o f the 
primary PCR product was used as template in the nested PCR reaction. The 
amplification program for SP1/SP2 PCR was as follows: dénaturation for 30 
seconds at 92°C, annealing for 30 seconds at 45°C, extension for 30 seconds at 
72°C for thirty cycles. The last extension was carried out for 3 minutes at 
72°C. Five microlitres o f nested PCR product were mixed with a 1-2 pi of 
lOX loading dye and analysed by agarose gel electrophoresis on a 1.5% 
agarose gel stained with ethidium bromide (0.8 pg/ml) in IX  Tris-acetate-
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EDTA buffer. DNA was visualised by ultraviolet transillumination and the 
expected nested PCR product band size o f 700 base pair was confirmed by 
comparison with a standard 100-base pair DNA molecular weight ladder.
2.6.3. Preparation o f dot-blot
For each sample that gave a positive resqlt by nested PCR, 20 pi o f PCR 
product was denatured with EDTA and NaOH to a final concentration of 
lOmM EDTA and 0.4 M NaOH, and incubated for 10 minutes at lOO^ ’C. Each 
denatured PCR product was then neutralized with an equal volume of 2 M 
ammonium acetate, pH 7 and blotted in duplicate onto a Genescreen nylon 
membrane (New England Nuclear, Houndslow, United Kingdom) using a dot- 
blotting apparatus (Bio-Rad, Hemel Hempstead, United Kingdom) according 
to the manufacturer’s instructions. H alf o f the denatured PCR product 
(equivalent to 10 pi o f PCR product) was placed in each o f two wells o f the 
dot-biotter. The duplicates were placed in different parts of the blot. Following 
transfer o f the DNA, the membrane was rinsed in 2 X SSC (0.15 M sodium 
chloride, 15 mM Trisodium citrate) for 1 minute, denatured in 0.4 M. NaOH 
for 1 minute and finally neutralized in a mixture of 1 M Tris-HCl and 1.5 M 
NaCl, pH 8 for 30 seconds. The blotted PCR products were fixed on the 
membrane by exposure to ultraviolet light in a UV cross-linker (Stratalinker, 
Stratagene, Amsterdam, The Netherlands) according to the manufacturer’s 
instructions.
2.6.4. Oligonucleotide probe labelling and hybridisation
In order to detect the DHFR  alleles associated with changes at amino acid 
positions 108, 51 and 59 by the dot-blot hybridisation technique, specific 
probes were designed and labeled with [y-^^P]-ATP (Abdel-Muhsin et al., 
2002). The sequences o f the probes and the specific hybridisation conditions 
are given in Table 4. The DHFR ThiTOS probe was not used because o f the 
same reason given above.
Ten picomoles (pmol) o f each probe were labelled using a single Ready-To-
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Go polynucleotide kinase reaction mix (Amersham Pharmacia Biotech Inc, 
Little Chalfont, United Kingdom) containing 10 units of T4 polynucleotide 
kinase, 50 mM Tris-HCl, (pH 7.6), 10 mM MgCE, 5 mM DTT, 0.1 mM 
spermidine, O.l mM EDTA (pH 8.0), 0.2 pM ATP and stabilizers in a total 
volume of 50 pi, to which 0.37 MBq (10 pCi) o f [y-^^PJ-ATP was added. Each 
probe was incubated with the labelling mixture at 37°C for 30 minutes and the 
unincorporated [y-^^P]-ATP was removed using Microspin G-25 columns 
(Amersham Pharmacia Biotech, United Kingdom) according to the 
manufacturer's instructions. Labelled probe was stored at -20°C until required. 
The nylon blot was prehybridised with hybridisation buffer [5 X SSPE (0.15 
M NaCl, 10 mM sodium phosphate, 1 mM EDTA), 5 X Denhardt’s reagent, 
0.5% sodium dodecyl sulphate (SDS), 0,02 mg/ml o f sonicated salmon sperm 
DNA] using 0.25-0.125 ml o f hybridisation solution per cm^ o f membrane. 
The membrane and buffer were incubated in a hybridisation oven with 
rôtisserie (with agitation) (Grant Boekel HIR 12, Cambridge, England) for > 
30 minutes at a temperature specific for each probe used (Table 4). The 
labelled and purified oligonucleotide probe was added to the hybridisation 
buffer (Ip l probe for every 1ml o f the hybridisation buffer) and the blot 
hybridised overnight at a temperature specific for the probe used (Table 4). 
The blot was washed once with 2 X SSC for 20 minutes and twice for 10 
minutes in 1 X SSC/ 0.1% SDS or 0.5 X SSC/ 0.1% SDS, at the temperature 
specific for each probe (Table 4).
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mTable 4
Oligonucleotide probes for the detection o f DHFR alleles o f P. falciparum  at 
positions 108, 51 and 59 and their dot-blot hybridisation conditions.
Probe Sequence (shown 5' to 3') Hybridisation
temperature
Stringent washes
D H F R -n ^
Asn-specific AACAAACTGGGAAAACATTCCAA 54.5°C [lXSSC/0.1% SDS]I0m in x2
(mutant)
Ser-specific AACAAGCTGCGAAAGCATTCCAA 50“C [lXSSC/0.1% SDS]10min x2
(wild type)
D H F R-5\
lie-specific ATGGAAATGTATTTCCCTAGAT 50°C [0.5XSSC/0.1%SDS]10min x2
(mutant)
Asn-specific ATGGAAATGTAATTCCCTAGAT 50°C [0.5XSSC/0.1%SDS]10min x2
(wild type)
DHFR-59
Arg-specific GAAATATTTTCGTGCAGTTAC 52°C [0.5X SSC/0.1 %SDS] 1 Omin x2
(mutant)
Cys-specific GAAATATTTTTGTGCAGTTAC 50“C [0.5XSSC/0.1%SDS]10min x2
(wild type)
The blot was wrapped in clingwrap and taped into an autoradiography cassette 
complete with intensifying screens. Location markers (Glogos II markers, 
Stratagene, Amsterdam, The Netherlands) were used to allow accurate 
positioning o f the autoradiograph and blot. Each blot was exposed to Kodak 
MXB X-ray film overnight at -70°C after v/hich the X-ray film was developed 
using an automatic developer
(X-OGRAPH Imaging system compact x 4). The probe was shipped from the 
blot with two washes in 0.1 M NaOH for 15 minutes each at room 
temperature. The blot was then rinsed briefly in 5 X SSC, air-dried, and then 
re-hybridised with other probes or kept at room temperature until required.
'
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Each blot was hybridised with each o f the probes shown in Table 4.
The blots were scored based on the specificity o f the controls. Experimental 
samples and controls were dot-blotted in duplicate to reinforce the correct 
scoring. Blots that had autoradiograph results with controls showing non­
specific hybridisation were given an extra stringent wash to ensure specificity. 
If this was not successful in removing the non-specific hybridisation, then the 
hybridisation and washing steps were re-optimised.
2.7. Statistical analysis methods
The results obtained were analysed using the Fisher’s Exact statistical test.
The R X C package (downloadable free software) 
[http://bioweb.usLi.edu/mpmbio/]) for the analysis of contingency tables 
(Mark P. Miller, 1997) was used for Fisher’s Exact statistical test instead o f 
the chi-squared test because most o f the numbers were small (less than 5 in the 
expected groups). The results were analysed to determine if;
(a) there was an association between the presence o f the mutation and 
treatment failure due to SP and a coiiibination o f CQ and SP.
(b) there was an association between the number o f mutations and time to
recrudescence following unsuccessful treatment with SP and a
combination o f CQ and SP.
The Chi-squared test was used to analyse if there was an association between 
age and clearance o f parasites with Pfcrt T76 mutation following treatment 
with CQ and SP.
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3. RESULTS AND DATA ANALYSIS:
3.1. SP/CQ efficacy tria l
3.1.1, Drug efficacy results
Of 106 patients recruited and treated with a combination o f SP and CQ, 53 
were judged to have adequate clinical response or parasites which were 
sensitive to the drug (S). Treatment failed in 48 patients, and the remaining 5 
patients were excluded at day 14 because they developed complications or 
changed treatment (supplied elsewhere) during the course o f follow-up.
(i) Monitoring the response to treatment by measuring parasitaemia, 52% of 
patients had sensitive parasites, 40% had parasites exhibiting an RI response,
6% an Rll response and 2% an RIII response. This indicated a drug failure rate 
of 48% (Table 5).
(ii) Measuring treatment outcome using clinical signs and symptoms, 92% of 
patients were judged to have an adequate clinical response, 2% an early 
treatment failure and 6% a late treatment failure. In this case, the total 
treatment failure rate was 8% (Table 6).
Table 5
SP/CQ drug resistance rate among evaluable cases o f uncomplicated P. falciparum  
malaria in Tororo. Outcome o f treatment was evaluated by parasitological 
examination.
SP/CQ
Parasitological Age 6- 59months
Outcome n (%)
Sensitive 53 (52.5)
RI 40 (39.6)
RII 6 (5.9)
RIII 2 (2.0)
Total 101 (100)
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Table 6
SP/CQ clinical outcomes among evaluable cases o f uncomplicated P. falciparum  
malaria in Tororo.
Therapeutic
Efficacy
SP/CQ
Age 6- 59months
n (%)
ACR 93 (92T)
LTF 6 (5.9)
ETF 2 (2.0)
Total 101 (100)
ACR= adequate clinical response, LTF= late treatment failure, ETF= early 
treatment failure
3,1.2. Genotyping results at M S P l and  M SP2 loci
Amplification o f DNA from 47 pairs o f isolates (day 0 and R) for the 
recrudescent or treatment failure group (RI-RIII) was performed for the M SPl 
and MSP2 loci. One RIII isolate was lost. The sample pairs were classified as 
follows, based on the combined results from both loci typed:
(a) If all PCR products in the day 0 sample were also present in the R sample 
and there were no additional fragments for both loci, this was considered a 
genuine recrudescence with all initial parasites recrudescing (all resistant) 
(Figure 3a).
(b) If PCR products in the day 0 sample were all completely different to those 
in the R sample this was considered evidence o f reinfection during follow- 
up (Figure 3b).
(c) If  all PCR products in the day 0 sample were present in the R sample but 
the R sample also had new PCR products this was considered a ‘mixed’ 
result in the R sample with mixtures o f drug resistant and new parasites 
(Figure 3c).
(d) If  the day 0 sample had some PCR products not in the R sample but the R 
sample had PCR products that were all present in the day 0, this was 
considered a recrudescence but with mixtures o f resistant and sensitive 
parasites in the day 0 sample (Figure 3d).
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Figure 3. Representation of gels of MSPl PCR products. Each box represents 
a gel. Lane 1 on each gel shows PCR products obtained after amplification of 
the MSPl locus of the day 0 DNA sample and lane 2 shows PCR products 
obtained after amplification of MSPl locus of the day of recrudescence (R) 
DNA sample, (a)-(d) represent different possible scenarios, where (a) and (d) 
are genuine recrudescences, (b) represents a reinfection and (c) a combination 
of recrudescence and reinfection. Results for MSP2 PCR products were 
similarly classified.
(a) (b) (c) (d)
1 2  1 2  1 2  1
Of the 47 pairs of isolates analysed, 10 (21%) had genuine recrudescent 
parasites as classified in Figure 3(a) and 3(d), none were entirely new 
infections, as shown in Figure 3(b), and 36 (77%) had both recrudescence and 
re-infections in the R sample as classified in Figure 3(c). One pair of isolates 
did not amplify for both loci (Table 7).
Table 7
Classification of MSPl and MSP2 PCR results for the responses in 47 children 
under the SP/CQ treatment group, in which the success of the drug treatment
Parasitological SP/CQ
Outcome n Rec. New Both Unknown
RI 40 9 0 30 1
Rll 6 0 0 6 0
RIII 1 1 0 0 0
Total 47 10 0 36 , 1
n refers to number of children examined.
Rec. refers to genuine recrudescence as classified in Figure 3(a) and (d).
New refers to entirely new infection as classified in Figure 3(b).
Both refers to recrudescence plus re-infection as classified in Figure 3(c). 
Unknown refers to the excluded samples that either did not amplify at one 
locus but did amplify at another locus or did not amplify at both loci.
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3.1.3. Genotyping at the Pfcrt 76 locus
DNA from 47 pairs of isolates for the clinical treatment failures or from 
parasites classified as RI to RIII was amplified at the Pfcrt locus to identify the 
alleles at codon 76 o f Pfcrt. One isolate in the RIII class went missing, hence a 
total o f 47 pairs (RI-RIII) were analysed instead o f 48 pairs as indicated in 
Table 5, DNA from 53 pre-treatment isolates from the patients who responded 
adequately to the drug was also subjected to PCR analysis.
O f the 53 patients whose parasitaemia cleared totally less than 7 days 
following SP/CQ treatment, 41 (77%) of their pre-treatment isolates were 
found to have parasites with the Pfcrt T76 (piutant) only, and none were found 
with the wild type allele only i.e. Pfcrt K76 (0%). The remaining 12 patients 
had parasites with both T76 and K76 alleles simultaneously (Table 8).
Table 8
Pfcrt allele prevalence in samples obtained from patients before SP/CQ treatment 
and patients with recurrent infection. M= mutant allele (T76), W= wild type allele
Allele at Pfcrt 76
SP/CQ
No. observed / total no. o f samples (%)
Before Treatment 
(S)
Before Treatment 
(RI-RIII)
After Treatment 
(RI-RIII)
Pfcrt T76 pure (M)
Pfcrt ICI e r n e  (w /m ) 
Pfcrt T76 Total 
Pfcrt K76 pure (W) 
Pfcrt K76 Total 
Did not amplify
41/53 (77.4) 
12/53 (22.6) 
53/53 (100) 
0
12/53 (22.6) 
0
39/47 (83.0) 
6/47(12.8) 
45/47 (95.7) 
0
6/47 (12.8) 
2/47 (4.3)
42/47 (89.4) 
3/47 (6.4) 
45/47 (95.7) 
0
3/47 (6.4) 
2/47 (4.3)
O f the 47 patients who did not clear their parasites within 7 days following 
SP/CQ treatment, 39 (83%) had pure Pfcrt T76 in their pre-treatment sample. 
This increased to 42 (89%) in the samples taken at recrudescence. Six patients 
(13%) had parasites present simultaneously with the T76 and with the K76 
allele in the pre-treatment samples, and this reduced to 3 (6%) in the samples 
taken at recrudescence. No samples pre-treatment and/or post-treatment 
contained only parasites with the Pfcrt K76 allele (Table 8). DNA extracted
51
from two of the pre-treatment samples and from two samples taken at 
recrudescence did not amplify.
Following genotyping at the M SPl and MSP2 loci, only ten o f the 47 patients 
with apparent resistant parasites were found to have genuine recrudeseences, 
with the remaining samples revealing the presence o f some novel parasites in 
the R sample, indicating that these patients had mixtures o f recrudescence and 
reinfection. The Pfcrfl6  alleles found in the ten genuine recrudescence only 
samples were as shown in Table 9.
Table 9
Pfcrt allele prevalence in samples obtained from patients before SP/CQ treatment 
and patients with genuine recrudescence infection only. M=mutant allele (T76),
SP/CQ
No. observed / tota no. o f samples (%)
Allele at Pfcrt 76 Before treatment (DO) After treatment (R)
(RI-RIII) (RI-RIII)
Pfcrt T76 pure (M) 7/10 (70) 7/10 (70)
Pfcrt K76/T76 (W/M) 2/10 (20) 2/10(20)
Pfcrt T76 Total 9/10 (90) 9/10 (90)
Pfcrt K76 pure (W) 0 0
Pfcrt K76 Total 2/10 (20) 2/10 (20)
Did not amplify 1/10(10) 1/10(10)
Seven patients (70%) had pure Pfcrt T76 in their pre-treatment isolates and 
seven (70%) had pure Pfcrt T76 in the recrudescent isolates. One (10%) 
patient had both the T76 and K76 alleles present simultaneously in both the 
pre-treatment sample and in the sample taken at recrudescence. No samples 
pre-treatment and/or post-treatment were found with Pfcrt K76 allele alone.
3. L 4. Statistical A nalysis o f results
The data from the 45 successfully typed treatment failure samples (Table 8) 
were analysed using Fisher’s Exact statistical test to see if there was an 
association between the presence of the Pfcrt T76 allele in the^ 2
pretreatment samples and treatment outcome measured by parasitaemia (Table 
10). No correlation could be seen (Fisher’s Exact P= 0.287). Excluding the 
samples with a mixture o f K76 and T76, there was also no correlation 
(Fisher’s Exact P= 1.000). When mixtures were grouped with the mutant class, 
there was also no correlation (Fisher’s Exact P= 1.000). The data were also 
analysed with respect to time to recrudescence. In this case the samples were 
divided into groups based on the time post-treatment at which recrudescent 
parasites appeared. The data were then analysed using a Fisher’s Exaet test to 
see if there was an association between the presence o f the Pfcrfïl(>  allele in 
the pretreatment samples and time to recrudescence (Table 11). Samples with 
a mixture or mutant and wild type alleles were not included as mutants but 
were analysed separately under the mixed (T76/K76) allele group. The results 
of the analysis (P= 0.114) indicated that there was no significant effect of the 
presence o f the mutant allele Pfcr(Y16 on time to recrudescence.
Table 10
Prevalence o f Pfcrt alleles in the pretreatment samples and response to SP/CQ, 
in which the success o f the drug treatment was measured by examination of
Allele at Pfcrt 
codon 76
Sensitive
(Pre-treatment)
RI-RIII
(Pre-treatment)
Total
(n)
T76 (M) 41 39 80
K76 (W) 0 0 0
K76/T76 (W/M) 12 6 18
Total 53 45 98
Fisher’s Exact P= 0.287.
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Table 11
Prevalence o f Pfcrt76 alleles in the pre-treatment samples within different 
time-to-recrudescenee groups for patients treated unsuccessfully with SP/CQ 
(RI-RIII).
Time Intervals 
(days)
K76 allele 
(Mutant)
T76 allele 
(Wild type)
T76/ K76 
(Mixed)
Total
(n)
D0-D7 2 0 0 2
D8-D14 5 0 0 5
D15-D21 15 0 0 15
D22-D28 17 0 , 6 23
Total (n) 39 0 6 45
Fisher’s Exact P== 0.114
The results (Table 8) show that all the ehildren with the infection who cleared 
their parasites and those who did not clear mutant parasites were found to 
carry the Pfcrt 76 mutation following SP/CQ treatment. Statistical analysis 
shows no association between the presence o f Pfcrt 76 mutation and treatment 
outcome measured by parasitaemia (Table 10). Host factors such as immunity 
are thought to contribute to clearance o f parasites resistant to CQ (Djimde et 
al., 2003, Djimde et al., 2001, Omar et al., 2001). Therefore age was used here 
as an indicator to estimate the level of a,ntiparasite immunity. The. results 
obtained for each individual were grouped according to age and analysed 
using the Chi squared test for the association between age and elearance of 
resistant parasites. When children o f all ages were considered, children 
infected with parasites carrying the PfcrtT76 mutation who cleared their 
parasites following SP/CQ treatment were not signifieantly different in age 
from those who did not el ear mutant parasites (X^=4.17, P=0.124) (Table 12). 
When children under one year old (6-12 months) were excluded from the 
analysis, because they were thought to be more likely to have maternal 
antibodies to the parasite, there was a significant association between 
clearance o f resistant parasites and age (X^=4.09, P=0.043) (Table 13).
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Table 12
Individuals carrying parasites with the Pfcrt T76 mutation in all age groups 
who did not clear and those who cleared the infection following SP/CQ 
treatment.
Age group 
(months)
Did not clear 
infection Cleared infection Total (n)
6-12 14 15 29
13-24 19 14 33
25-49 12 24 36
Total (n) 45 53 98
Table 13
Individuals carrying parasites with the Pfcrt  ^ T76 mutation in older age groups 
who did not clear and those who cleared the infection.
Age group 
(months)
Did not clear 
infection Cleared infection Total (n)
13-24 19 14 33
25-49 12 24 36
Total (n) 31 38 69
X^=4.09, P= 0.043
3.1.5. PCR/dot-blot hybridisation at the DHFR locus 
The 47 isolates from the RI-RIII group were typed at the M SPl locus to 
determine if they were genuinely recrudeseent. By this method 22/47 isolates 
were classified as recrudeseent and 2 2 1 were classified as having both 
recrudeseent parasites and reinfections. Three did not amplify. The 22 isolates 
showing apparent recrudescence by M SPl were PCR/dot-blot hybridised at 
the DHFR locus to identify alleles at codons 108, 51 and 59 (Table 15). The 
remaining 25 isolates classified as having both recrudeseent parasites and 
reinfeetions including those that did not amplify by PCR were intentionally 
not hybridised by PCR/dot-blot because one o f the main aims o f the work 
involved identifying drug resistant and sensitive alleles from isolates
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classified as genuinely recrudeseent. After the dot-blot hybridisation analysis 
had been carried out, it was discovered that 12 o f the original 36 isolates were 
in fact not genuinely recrudeseent. Subsequent analysis by typing at the MSP2 
locus revealed the presence of additional novel parasites in the R sample, 
indicating that these patients represented mixtures o f recrudescence and 
reinfection. To take this into account, the statistical analyses were done on the 
total blotted samples (n = 22) and separately on the genuine recrudescents only 
(11= 10).
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3.1.6. m W H  codon 108
O f the 22 patient DNA samples analysed by PCR/dot-blot hybridisation, all 
(100%) were typed as having pure DHFR Asn 108 (mutant form) in their pre- 
treatment isolates, and 21 (representing 100% of the samples suceessfully 
typed) had pure Asn 108 in the samples taken at recrudeseence (Table 15). 
One isolate from the post- treatment isolates (an RIII response) failed to 
amplify by SP1/SP2 PCR, and therefore it was not included on the dot-blot. 
No samples pre-treatment and post-treatment were found with the allele 
encoding DHFR Ser 108 (wild type) alone and no samples were found with 
both alleles encoding Ser 108 and Asn 108 in the pre-treatment and/or post 
treatment isolates. In summary, all the isolates possessed the allele encoding 
Asn 108 alone, regardless o f time taken to recrudescence. Therefore there is 
no correlation between the presence o f alleles encoding Asn 108 and time to 
reerudescenee following SP/CQ treatment (Table 16).
Equally, for the 10 genuine recrudescent subset of samples, all the day 0 and R 
samples had the allele encoding Asn 108, (Table 14), and there was no 
correlation with the time to recrudescence (Fisher’s Exact P= 1.000).
Table 16
Prevalence o f D/ZFR108 alleles in the pre-treatment samples within different 
time to recrudescence groups for patients treated unsuccessfully with SP/CQ.
Time Intervals 
(days)
Asn 108 
(Mutant)
Ser 108 
(Wild type)
108 Asn + 108  
Ser (Mixed)
Total (n)
D0-D7 ■ 1 0 0 1
D8-D14 1 0 0 1
D15-D21 7 0 0 7
D22-D28 13 0 0 13
Total (n) 22 0 0 22
Fisher’s Exaet, P= 1.000
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3.1.7. D H FR codon 51
Twenty one (95.5%) patients out o f 22 had only parasites with the allele 
encoding DHFR 51 He (mutant form) in their pre-treatment samples. Nineteen 
o f these had only parasites with the allele encoding DHFR 51 He in their 
recrudeseent samples, representing 100% of those successfully typed, as 2 
isolates taken at recrudescence (RI) were negative by PCR. One patient, who 
had an RIII response, had a mixture o f the alleles encoding 51 Asn (wild type) 
and 51 He present in their pre-treatment sample but DNA from their post 
treatment sample failed to amplify. No samples pre- and post-treatment were 
found to possess only parasites with the allele encoding 51 Asn.
In summary, all the isolates except one possessed the allele encoding mutant 
form (51 He) alone, regardless o f time taken to recrudescence. There was no 
correlation between the presence o f alleles encoding 51 He and time to 
recrudescence following SP/CQ treatment (Table 17). For the subset o f these 
samples showing genuine recrudescence with M SPl and MSP2 typing, nine 
out of ten had only alleles encoding 51 He, and there was no correlation 
between the presence o f 51 He and the tiipe to recrudescence (Fisher’s exact 
P= 0.108).
Table 17
Prevalence o f DHFR 51 alleles in the 22 pre-treatment samples within 
different time to recrudescence groups for patients treated unsuccessfully with 
SP/CQ.
Time Intervals 
(days)
51 Asn 
(Wild type alone)
51 He 
(Mutant alone)
5 Hie + 51 Asn 
(Mixed)
Total
(n)
D0-D7 0 0 1 1
D8-D14 0 1 0 1
D15-D21 0 7 0 7
D22-D28 0 13 0 13
Total (n) 0 21 1 22
Fisher’s Exact P= 0.093
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3.1.8. D B F K  codon 59
Three patients out o f 22 had only parasites with the allele encoding DHFR 59 
Arg (mutant form) in their pre-treatment isolates (Table 18). Two o f these 
patients had the allele encoding DHFR 59 Arg in their post- treatment isolates; 
the remaining patient had both alleles 59 Arg and 59 Cys (wild type) present 
in their post-treatment isolate. Overall 8 post-treatment isolates had only 
parasites with the allele encoding DHFR 59 Arg; six o f these had both alleles 
encoding DHFR 59 Arg and DHFR 59 Cys in their pre-treatment isolates, 
indicating selection for the DHFR  59 Arg allele following unsuccessful 
treatment with the SP/CQ combination. Seventeen (77.3%) patients had both 
the DHFR 59 Cys and DHFR  59 Arg alleles present simultaneously in their 
pre-treatment isolates. Two (9.1%) pre-treatment isolates and 5 (22.7%) 
isolates at recrudescence had only parasites with the allele eneoding DHFR 59 
Cys. One isolate taken at recrudescence (RIII) failed to amplify by SP1/SP2 
PCR.
The results o f DHFR  59 typing of the subset o f 10 genuine recrudeseent 
samples are shown in Table 19.
Table 18
Prevalence o f DHFR  59 alleles in the 22 pre-treatment samples within 
different time to reerudescenee groups for the patients treated unsuccessfully 
with SP/CQ.
Time Intervals 
(days)
59Cys (Wild 
type alone)
5 9Arg (Mutant 
alone)
59Cys + 5 9 Arg 
(Mixed)
Total
(n)
D0-D7 0 0 1 1
D8-D14 0 0 1 1
D15-D21 1 1 5 7
D22-D28 1 2 10 13
Total (n) 2 3 17 22
Fisher's Exaet P=1.000 treating mixtures as a separate group 
Fisher's Exact P=1.000 grouping mixtures with mutant group
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Table 19
Prevalence o f DHFR  59 alleles in the 10 genuinely recrudeseent samples 
within different time to recrudescence groups for the patients treated 
unsuccessfully with SP/CQ.
Time Intervals 
(days)
59Cys (Wild 
type alone)
5 9Arg (Mutant 
alone)
59Cys + 5 9 Arg 
(Mixed)
Total
(n)
D0-D7 0 0 1 1
D8-D14 0 0 0 0
D15-D21 1 0 4 5
D22-D28 0 1 3 4
Total (n) 1 1 8 10
Fisher's Exact P=1.000 treating mixtures as a separate group 
Fisher’s Exaet P=1.000 grouping mixtures with mutant group
Fisher's Exact tests were used to see if  parasites in the 22 sample set carrying 
the double mutant forms DHFRIOZ Asn/51Ile and DHFRIQ^ Asn/59Arg were 
found at different frequencies in the pre-treatment samples o f patients who had 
early rather than late reerudeseences (Table 20). No significant differences 
were observed. The same analysis was carried out looking at the triple mutant 
form (79HF7^108Asn/51Ile/59Arg) (Table 21) with no significant difference 
observed.
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Table 20
Prevalence o f double mutant haplotypes o f D7/FR108/51 and D7/FR108/59 in 
the 22 pre-treatment samples within different time-to-recrudescenee groups for 
patients treated unsuccessfully with SP/CQ.
Time
Intervals
(days)
Pure double 
mutant form 
(108Asn/51Ile)
Other
alleles
1
Pure double 
mutant form 
(108Asn/ 59Arg)
Other
alleles
Total
(n)
D0-D7 0 1 0 1 1
D8-D14 1 0 0 1 1
D15-D21 7 0 1 6 7
D22-D28 13 0 2 11 13
Total (n) 21 1 3 19 22
Fisher's Exact P=0.088 (lOSAsn/ 51Ile); P=1.000 (108Asn/ 59Arg).
Table 21
Prevalence o f triple mutant haplotype o f DÆFR108/51/59 in the 22 pre­
treatment samples within different time to ^reerudescenee groups for patients 
treated unsuccessfully with SP/CQ.
Time
Intervals
(days)
Pure triple mutation 
(108Asn/51Ile/59Arg)
Other alleles Total
(n)
D0-D7 0 1 1
D8-D14 0 1 1
D15-D21 1 5 6
D22-D28 2 10 12
Total (n) 3 17 20
Fisher’s Exact P= 1.000
Considering the subset o f 10 samples (geiiuine recrudescents), there was no 
significant difference in the frequency o f the double mutant forms in early 
rather than late treatment failure groups (DÆER108A sn/51 Ile:P=0.106; or 
DÆFR108Asn/59Arg: P=0.508) (Table 22).
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Table 22
Prevalence o f double mutant haplotypes o f DHFR\QW5\ and D H FRXW 59  in 
the pre-treatment samples within different time-to-recrudescence groups for 
the subset o f 10 patients treated unsuccessfully with SP/CQ.
Time
Intervals
(days)
Pure double 
mutant form 
(lOSAsn/51Ile)
Other
alleles
Total
(n)
Pure double 
mutant form 
(lOSAsn/ 59 Arg)
Other
alleles
Total
(n)
D0-D7 0 1 1 0 1 1
D8-D14 0 0 0 0 0 0
D15-D21 5 0 5 0 5 5
D22-D28 4 0 4 1 3 4
Total (n) 9 1 10 1 9 10
Fisher's Exact P= 0.106 (lOSAsn/ 5Hie); P= 0.508 (lOSAsn/ 59Arg)
Table 23
Prevalence o f triple mutant haplotype ofDE/FRl 08/51/59 in the pre-treatment 
samples within different time to recrudescence groups for the subset o f 10
Time Intervals 
(days)
Pure triple mutation 
(108Asn/51Ile/59Arg)
Other
alleles
Total
(n)
D0-D7 0 1 1
D8-D14 0 0 0
D15-D21 0 5 5
D22-D28 1 n 3 4
Total (n) 1 9 10
Fisher’s Exact P= 0.504
3.2. SP efficacy tria!
3.2.1. Drug efficacy results
Out o f 88 patients recruited and treated with SP alone, 31 were judged to have 
an adequate clinical response (ACR), or to have been infected with parasites 
which were sensitive to the drug. Treatment failed in 49 patients. Three
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patients were excluded at day 14 because o f changing treatment, 2 were lost to 
follow-up at day 14 and 3 were lost to follow-up between day 14 and 28.
(i) Monitoring response to treatment outcome measured by parasitaemia, 39% 
of the patients had sensitive parasites, 53% had parasites exhibiting an RI 
response, 1% an RII response and 8% an RIII response. This indicated a drug 
failure rate o f 62% (Table 24).
(ii) Measuring treatment outcome using clinical signs and symptoms, 91% of 
the patients were judged to have an adequate clinical response, 6% an early 
treatment failure and 1% a late treatment failure. The total treatment failure 
rate, as measured by clinical symptoms and signs alone, was 7% (Table 25).
Table 24
SP drug resistance rate among evaluable cases o f uncomplicated P. falciparum  malaria 
in Tororo. Treatment outcome was evaluated by parasitological examination.
treatment failure
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SP
Parasitological Age 6- 59months
Outcome n (%)
Sensitive 31 (38.8)
RI 42 (52.5)
RII 1 (1.3)
RIII 6 (7.5)
Total 80 (100)
1
Table 25 3:
SP clinical outcome among evaluable cases o f uncomplicated P. falciparum 1
malaria in Tororo
SP
Therapeutic Age 6- 59months
Efficacy n (%) ■
ACR 73 (91.3)
LTF 1 (1.3) J
ETF 6 (7.5)
Total 80 (100) 4^
3.2.2. Genotyping results at the MSPl and MSP2 loci 
Amplification o f DNA from 48 pairs o f isolates (day 0 and R) for the 
recrudescent or treatment failure group (RI-RIII) was performed for the M SPl 
and MSP2 loci. The sample pairs were classified in the same way as for the 
SP/CQ trial. One sample under the RI class went missing therefore a total o f 
48 pairs were analysed and not 49 as indicated in Table 24.
O f the 48 pairs o f isolates analysed, 13 (27%) had genuine recrudeseent 
parasites, three (6%) were entirely new infections and 32 (67%) were mixtures 
o f some recrudescence but also with evidence o f reinfection in the R sample 
(Table 26).
Table 26
Classification o f M SP l and MSP2 PCR results for the responses in 48 children 
under the SP treatment group, in which the success o f the drug treatment was
Parasitological Characterisation o f recrudeseent infection
Outcome n Rec New Both Unknown
RI 41 8 3 30 0
RII i 0 0 1 0
RIII 6 5 0 1 0
Total 48 13 3 32 0
n refers to number o f children examined.
Rec. refers to recrudescence as classified in Fig 3 (a) and (d).
New refers to entirely new infection as classified in Fig 3 (b).
Both refers to recrudescence plus re-infection as classified in Fig 3 (c). 
Unknown refers to excluded samples that did not amplify.
3.2.3. PCR/Dot-blot hybridisation at the DHFR locus 
The 48 isolates from the RI-RIII group were typed at the M SP l locus to 
determine if they were genuinely recrudescent. By this method 33/48 isolates 
were classified as recrudeseent and eight (16.7%) were classified as having 
both recrudeseence and reinfections. Six (12.5%) isolates were classified as 
reinfections. DNA from one isolate did not amplify. The 33 isolates showing 
apparent recrudeseence by M SPl were PCR/dot-blot hybridised at the65
DHFR locus to identify alleles at codons 108, 51 and 59 (Table 27). The 
remaining 15 isolates classified as having both recrudeseent and reinfections, 
only reinfections and those that failed to amplify by PCR were intentionally 
not hybridised by dot-blot PCR for the same reason as stated for the SP/CQ 
drug trial. After the dot-blot hybridisation analysis had been carried out, it was 
discovered that 20 o f  the original 33 isolates were in fact not genuinely 
recrudeseent. Subsequent analysis by typing at the MSP2 locus revealed the 
presence o f novel parasites in the R sample, indicating that these patients 
hadmixtures o f recrudescence and reinfection. Having taken this into account, 
the statistical analyses were done on the total blotted samples (n= 33) and 
separately on the genuine recrudescents only (n=13).
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3.2,4. codon 108
O f the patient isolates analysed by PCR /dot-blot hybridisation, all 33 (100%) 
had DHFR alleles encoding pure Asn 108 (mutant form) in their pre-treatment 
isolates, and 30 (representing 100% o f the samples successfully typed) had 
DHFR alleles encoding pure Asn 108 in the samples taken at recrudeseence 
(Table 27). No samples pre-treatment and post-treatment had DHFR  alleles 
encoding Ser 108 (wild type) alone, and no samples were found with both 
alleles encoding Ser 108 and Asn 108 alleles in the pre-treatment and/or post­
treatment isolates (Table 27). DNA from three isolates from the post-treatment 
group (two RI & one RIII responses) failed to amplify by SP1/SP2 PCR, and 
therefore they were not included on the dot-blot. All the isolates possessed the 
allele encoding Asn 108 alone regardless o f time taken to recrudescence. 
Therefore there is no correlation between the presence o f DHFR alleles 
encoding Asn 108 and time to recrudescence following SP treatment 
(Table 29).
Equally for the 13 genuinely recrudeseent subset o f samples, all day 0 and R 
samples had DHFR alleles encoding Asn 108 (Table 28), and again there was 
no correlation with time to recrudescence (Fisher’s Exact P= 1.000).
Table 29
Prevalence o f  DHFR 108 alleles in the pre-treatment samples within different
Time Intervals 
(days)
Asn 108 
(Mutant)
Ser 108 
(Wild type)
108 Asn + 108 Ser 
(Mixed)
Total
(n)
D0-D7 5 0 0 5
D8-D14 0 0 0 0
D15-D21 13 0 0 13
D22-D28 15 0 0 15
Total (n) 33 0 0 33
Fisher’s Exact P= 1.000.
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3.2.5. DHFR codon 51
Twenty seven patients out o f  33 had only parasites encoding DHFR 5 1 He 
(mutant form) in their pre-treatment samples. This represents 100% o f those 
successfully typed, as six isolates (RI) were negative by PCR. Twenty three 
(85%) o f these had only parasites with DHFR encoding 51 He in their 
recrudescent samples. One patient, who had an RI response, had parasites 
encoding both 51 Asn (wild type) and 5 Hie present simultaneously in the 
sample taken at recrudescence. No patient had both alleles present in the pre­
treatment isolates. One patient, who had an RI response, had only parasites 
encoding DHFR 51 Asn present in the sample taken at recrudescence. None of 
the isolates pre-treatment contained parasites encoding DHFR 51 Asn (Table 
27). Eight isolates (two RIII and six RI) taken at recrudescence were negative 
by PCR. In summary, all the DO isolates possessed only parasites with the 
mutant form (DHFR 5 Hie) regardless o f time taken to recrudescence. There 
was no correlation between the presence o f alleles encoding DHFR 51 He and 
time to recrudescence following SP treatment (Table 30).
For the subset o f 13 samples showing only genuine recrudescence patterns, all 
(100%) had parasites encoding DHFR 51 He in the DO sample and therefore 
there was no correlation between the presence o f DHFR 5 Hie and time to 
recrudescence.
Table 30
Prevalence o f DHFR 5 1 alleles in the pre-treatment samples within different 
time-to-recrudescence groups for patients treated unsuccessfully with SP.
Time Intervals 
(days)
51 Asn 
(Wild type alone)
51 He 
(Mutant alone)
51 Asn + 51 He 
(Mixed)
Total
(n)
D0-D7 0 5 0 5
D8-D14 0 0 0 0
D15-D21 0 10 0 10
D22-D28 0 12 0 12
Total (n) 0 27 0 27
Fisher’s Exact P= .000
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3.2,6. DHFR codon 59
Six patients out o f the 33 had only parasites with the DHFR allele encoding 
59Arg (mutant form) in their pre-treatment isolates. All six o f these patients 
had parasites encoding DHFR 59Arg only in their post-treatment isolates. Out 
o f the 33 patients, 19 (58%) had a mixture o f parasites encoding DHFR 59Cys 
and DHFR 59Arg in the DO samples; in the recrudescent samples, three (10%) 
remained mixed, two lost the parasites encoding DHFR 59Arg and became 
DHFR 59Cys only, and the remainder (12) lost the parasites encoding DHFR 
59Cys and became DHFR 59Arg only, indicating selection o f parasites 
encoding the mutant form at DHFR  59 following unsuccessful treatment with 
SP. Eight (24%) patients had parasites encoding DHFR 59Cys only at DO but 
at recrudescence five o f these samples became DHFR 59Arg only. The other 
two (7%) samples had a mixture o f parasites encoding DHFR 59Cys and 
DHFR 59Arg at recrudescence (Table 27). Three (9%) isolates taken at 
recrudescence (one RIII and two RI) failed to amplify by SP1/SP2 PCR.
When the samples with mixed (wild type and mutant) forms o f DHFR 59 were 
included in the mutant class (Table 31), there was no association between the 
allele present and time to recrudescence. When the mixed class was treated as 
a separate group (Table 32), there was an association between the allele 
present and time to recrudescence (P= 0.021).
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Table 31
Prevalence o f DHFR 59 alleles in the 33 pre-treatment samples within 
different-time-to recrudescence groups for the patients treated unsuceessfully 
with SP.
Time Intervals 
(days)
59 Cys 
(Wild type alone)
59 Cys/Arg 
(Mutant/ Mixed)
Total
(n)
D0-D7 0 5 5
D8-D14 0 0 0
D15-D21 4 9 13
D22-D28 4 11 15
Total (n) 8 25 33
Fisher’s Exact P= 0.486 grouping mixtures with mutant group
Table 32
Prevalence o f DHFR 59 alleles in the 33 pre-treatment samples within 
different time to recrudeseence groups for the patients treated unsuccessfully 
with SP.
Time Intervals 
(days)
59 Arg 
Mutant)
59 Cys 
(Mild type)
59 Cys/Arg 
(Mixed)
Total
(n)
D0-D7 4 0 1 5
D8-D14 0 0 0 0
D15-D21 1 4 8 13
D22-D28 1 4 10 15
Total (n) 6 8 19 33
isher’s Exact P= 0.021 treating mixtures as a separate group
For the subset o f 13 samples that were genuine recrudescents, analysing the 
DHFR 59 pretreatment results (Table 33) by Fisher’s Exact test indicated no 
association between the presence o f the allele in the pretreatment sample and 
time to recrudeseence if  the mixtures (wild type and mutant forms o f DHFR 
59) were grouped with the mutant class. A slight association was observed if 
mixtures were treated as a separate group (P=0.055) but this was not quite 
significant at the 5% level.
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Table 33
Prevalence o f DHFR  59 alleles in the 13 genuinely recrudescent samples 
within different time-to-recrudescence groups for the patients treated 
unsuccessfully with SP.
Pre-treatment Post-treatment
Time
Intervals
(days)
59 Cys 
(wildtype 
alone)
59 Arg 
(mutant 
alone)
59 Cys 
+ 59Arg 
(mixed)
Total
(n)
59 Cys 
(wildtype 
alone)
59 Arg 
(mutant 
alone)
59 Cys 
+ 5 9 Arg 
(mixed)
Total
(n)
D0-D7 0 4 1 5 0 4 0 4
D8-D14 0 0 0 0 0 0 0 0
D 15-021 1 1 2 4 0 3 1 4
022-028 0 0 4 4 0 4 0 4
Total (n) 1 5 7 13 3 11 1 12
Fisher’s Exact P=0.055 treating mixtures as a separate group 
Fisher’s Exact P=0.631 grouping mixtures with mutant group 
Fisher’s Exact tests were used to analyse if  parasites in the 33 sample set 
carrying the double mutant (108Asn/51Ile or 108Asn/59Arg) were found at 
different frequencies in the pre-treatment samples o f patients who had early 
rather than late recrudescence (Table 34). There was no significant effect 
observed for DHFR  108Asn/51Ile. The P value (0.0016) was highly 
significant for DHFR 108Asn/59Arg indicating a correlation between the 
presence o f the double mutation and time to recrudescence, i.e. parasites with 
the double mutation recrudesced significantly earlier than those without.
The same analysis was carried out for the triple mutant ( 108Asn/51 Ile/59Arg). 
A highly signifieant effect was observed (P= 0.0009) (Table 35).
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Table 34
Prevalence o f double mutant haplotypes o f DHFRlOS/51 and DHFRlOS/59 in 
the 33 pre-treatment samples within different time-to-recrudescence groups for
Time
Intervals
(days)
Pure double 
mutant form 
(lOSAsn/ 51 He)
Other
alleles
Total
(n)
Pure double 
mutant form 
(lOSAsn/59Arg)
Other
alleles
Total
(n)
D0-D7 5 0 5 4 1 5
D8-D14 0 0 0 0 0 0
D15-D21 11 0 11 1 12 13
D22-D28 11 0 11 1 14 15
Total (n) 27 0 27 6 27 33
Fisher’s Exact P= 1.000 (lOSAsn/ 51Ile); P= 0.0016 (lOSAsn/ 59Arg)
Table 35
Prevalence o f triple mutant haplotype o f DHFRlQS/51/59 in the 33 pre­
treatment samples within different time-to-recrudescence groups for patients
Time Intervals 
(days)
Pure triple mutation 
(10 8 Asn/51 Ile/5 9 Arg)
Other
alleles
Total
(n)
D0-D7 4 1 5
D8-D14 0 0 0
D15-D21 0 10 10
D22-D28 1 11 12
Total (n) 5 22 27
Fisher’s Exact P= 0.0009
The Fisher's Exact test was used to analyse the subset o f 13 samples that were 
genuinely recrudescent only. Parasites carrying the double mutant 
(108Asn/51Ile) were not found at different frequencies in the pre-treatment 
samples o f patients who had early rather than late recrudescence (P= 1.000) 
(Table 36). Parasites carrying the double mutant form DF/Fi?108Asn/59Arg 
were found at significantly higher frequencies in early rather than late
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recrudescences (P=0.0479). Parasites with the triple mutation 
(Z>/7Fi?108Asn/51Ile/59Arg) were also significantly more frequent in early 
rather than late recrudescences (P== 0.028) in the 13 sample subset (Table 37).
Table 36
Prevalence o f double mutant haplotypes o f OTZFf^l 08/51 and DiTF/^l 08/59 in 
the pre-treatment samples within different time-to-recrudescence groups for 
the subset o f 13 patients treated unsuccessfully with SP.
Time
Intervals
(days)
Pure double 
mutant form 
(lOSAsn/51Ile)
Other
alleles
Total
(n)
Pure double 
mutant form 
(lOSAsn/ 5 9 Arg)
Other
alleles
Total
(n)
D0-D7 5 0 5 4 1 5
D8-D14 0 0 0 0 0 0
D15-D21 3 0 3 1 3 4
D22-D28 4 0 4 0 4 4
Total (n) 12 0 12 5 8 13
Fisher’s Exact P=1.000 (108Asn/ 51 He); P= 0.048 (108Asn/ 59Arg)
Table 37
Prevalence o f triple mutant haplotype o f DHFRlOS/51/59 in the pre-treatment 
samples within different time to recrudescence groups for the subset o f 13
Time Intervals 
(days)
Pure triple mutation 
(108Asn/51Ile/59Arg)
Other
alleles
Total
(n)
D0-D7 4 1 5
D8-D14 0 0 0
D15-D21 0 3 3
D22-D28 0 4 4
Total (n) 4 8 12
Fisher’s Exact P= 0.028
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Figure 4. Dot-blot of PCR products of P. falciparum pre-/ post-treatment 
isolates from patients treated with SP and SP/CQ hybridised with the DHFR 
59 Arg-specific oligonucleotide probe in the upper and Cys-specific probe in 
the lower panels.
Positions A1 - A3 in both panels contain P. falciparum clones 3D7, HB3 & 
Dd2 respectively. Positions A4 - A5 in both panels contain negative controls 
(water). Positions A6- C3 in both panels contain patients falciparum isolates 
(sample numbers: 41 (R), 117 (DO), 119 (R), 121 (R), 124 (R), 137 (R), 158 
(R), 177 (R), 201 (R), 230 (R), 254 (R), 73 (DO), 73 (R), 82 (R), 97 (DO), 156 
(DO), 206 (R), 228 (DO) and 228 (R)- see Appendix 1). Below is a schematic 
showing the results for each spot.
Figure 5. Representation of the dot-blot of hybridised PCR products. Each 
spot is a hybridised PCR product for a specific probe.
O - a hybridised PCR product showing a positive signal for the Cys- probe.
0  - a hybridised PCR product showing a positive signal for the Arg- probe. 
#  - a hybridised PCR product showing a positive signal for both the Cys and 
Arg- probes.
Q - a hybridised PCR product showing no signal for both the Cys and Arg 
probes.
4. DISCUSSION:
Several studies associating mutations in DHFR, DHPS and Pfcrt genes with 
treatment outcome following treatment o f patients with SP and CQ 
respectively have been done. However, no study has been done to see whether 
there is an association between the number o f mutations in the pyrimethamine 
resistance gene (DHFR) and the time to recrudescence or treatment failure 
following treatment with SP and the combination SP/CQ. Our work has 
therefore been the first to address this issue.
The work presented here has considered whether the number o f mutations 
found in the parasite gene PfDHFR has an effect on the level o f in vivo 
resistance, as measured by time to recrudescence o f parasites or symptoms of 
malaria. The hypothesis was that parasites with two or three altered amino 
acids at the known key sites in this gene would have increased resistance to 
the drug, and would grow faster in the presence o f therapeutic drug levels than 
parasites with only one altered amino acid. The children studied were taking 
part in two antimalarial drug efficacy trials, one o f SP and one o f SP plus CQ, 
the latter being the first line treatment for uncomplicated malaria in Uganda 
since 2001 (Communication from the Ministry o f Health, Malaria Control 
Programme).
4.1. Clinical and Parasitological outcome
Treatment o f children with a combination o f SP/CQ was clinically effective 
with an adequate clinical response rate o f 92%. At the level o f parasite 
clearance rates, SP/CQ was less effective with only 53% o f the children 
clearing their parasitaemia. Roughly 70% o f the children had evidence o f new 
infections with parasites during the follow-up period, accompanied by the 
persistence o f  parasites from the initial infection. Although the study was 
carried out in an area o f high transmission, this may not indicate a high level 
o f re-infection during the follow-up period. Only one sample was taken at 
admission, and therefore parasites that were sequestered, or in the liver stages, 
at the time o f sampling could have been missed. Therapeutic blood levels of
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CQ persist for 6-10 days (White, 1998) and those o f SP following the usual 
dose persist for 15-52 days (Watkins and Masobo, 1993). Synergistic activity 
between sulfadoxine and pyrimethamine is lost after approximately 15 days 
and after this period, parasites respond only to pyrimethamine (Watkins and 
Masobo, 1993). Based on this, early recrudescences are therefore likely to be 
o f drug resistant parasites as both drugs (SP/CQ) will still be at therapeutic 
levels; however shortly after 10 days for CQ and 15 days for SP, 
recrudescences could be o f parasites with lower levels o f resistance to CQ and 
pyrimethamine. Very late recrudescences could be o f parasites sensitive to SP 
but probably resistant to pyrimethamine. It is also likely that the novel 
parasites appearing in early recrudescences will be resistant to SP, whereas 
those appearing later on could be sensitive to SP.
The clinical outcome following treatment with SP was very similar to that of 
the SP/CQ arm o f the study. Adequate clinical response following treatment 
with SP was slightly lower than that following treatment with SP/CQ (91% 
ACR); and parasite clearance rates were also lower, with parasitaemia cleared 
in only 39% of the children treated with SP, compared to 53% with SP/CQ 
although this was not statistically significant (Fisher’s Exact P= 0,3).
The level o f overall recrudescence in the two drug treatment regimes was 
similar. In the SP/CQ arm of the study, there was no evidence o f total parasite 
clearance followed by re-infection during the follow-up period. By contrast in 
the SP arm of the study, three children were typed with totally novel parasites 
that were present in the recrudescent sample but not in the initial sample, 
indicating the clearance o f the original parasitaemia by the drug, but re­
infection during the follow-up period. These three children were recrudescent 
at 16, 21 and 28 days post-treatment. Since the synergistic activity between 
sulfadoxine and pyrimethamine lasts for approximately 15 days after which 
the reappearing parasites respond only to pyrimethamine, then the reinfecting 
parasites in the first child are most probably resistant to SP. The reinfecting 
parasites in the other two children could have been SP-sensitive but most
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probably pyrimethamine resistant. Although this difference between the two 
drug regimens may be due to chance alone, it is possible that the CQ remains 
at levels suppressive for sensitive parasites, for 1-2 months (Krishna and 
White, 1996) which is much longer than for the synergistic effect o f SP at 15 
days (Watkins and Masobo, 1993) and therefore this could prevent the growth 
o f reinfecting, drug-sensitive parasites. In the SP arm of the study once the 
levels o f SP had dropped to sub-therapeutic levels, this then could allow 
reinfecting parasites to grow in treated children. In the SP/CQ arm, such 
parasites could have encountered therapeutic levels o f both CQ and SP.
4.2. Mutations in pfcrt76 and resistance to SP/CQ
The pre- and post- treatment samples from those in whom SP/CQ treatment 
failed to clear parasitaemia were genotyped at the Pfcrtl6  locus. All (100%) of 
the pre- and the post-treatment samples possessed parasites with the mutant 
allele PfcrfTlS, which confers resistance to CQ in vitro. No infections in 
either the pre- or post-treatment samples were found to contain only wild type 
parasites. O f the post-treatment samples, 89% were infections with parasites 
carrying the mutant P fcrtl6  allele only, the remainder (6%) being multiple- 
done infections o f parasites carrying both mutant (T76) and wild type (K76) 
Pfcrt alleles. This was surprising, as it might have been expected that CQ 
would kill parasites carrying the K76 allele in multiple clone infections, but 
this was apparently not the case. One possible explanation for this could be 
poor drug absorption and/or fast metabolism of CQ in these children. It is also 
possible some clinical resistance to CQ could be the result o f  mutations in 
genes other than Pfcrt.
Typing o f the pre-treatment samples o f individuals in whom SP/CQ was 
successful in clearing parasitaemia showed that P fcrtH 6  is also present in 
100% in samples (23% of these being multiple clone infections where the K76 
is also present) (Table 8). The PfcrtT16 allele therefore appears to be at very 
high prevalence in this region o f Uganda. Despite this, treatment failure rates 
with CQ alone (the previous first line drug in Uganda until 2001, when it was 
replaced by SP/CQ) were estimated at 30 % (Ministry o f Health)
78
There appeared to be no correlation between the presence o f parasites carrying 
the mutated form o f  Pfcrtl6  and treatment failure with SP/CQ in this 
population. Overall for the data from this drug treatment regimen, it would 
appear that the presence o f the Pfcr(X16 mutation had no influence on 
treatment failure with the drug combination SP/CQ. It is likely that the SP 
component o f the drug combination is responsible for treatment outcome or
[http://www.health.go.ug/malaria.htm]). It is obvious that in this area, the 
Pfcrtl6  mutation is not predictive o f CQ treatment failure, and it is likely that 
mutations in other genes, such as pfm drl (Babiker et a l, 2001, Dorsey et a l, 
2001, Mockenhaupt et a l, 2001) are necessary for clinical treatment failure. 
Host factors such as immunity may also contribute to clearance o f parasites 
resistant to CQ. The level o f antiparasite immunity is difficult to measure, but 
age can be used as an indicator (Djimde et a l,  2003, Djimde et a l ,  2001, 
Omar et a l ,  2001). There was no significant difference in age between 
children infected with parasites carrying the Pfcrtl6  mutation who cleared 
their parasites following SP/CQ treatment and those who did not clear mutant 
parasites (P=0.124) when children o f all ages were considered. Excluding 
children under one year old (6-12 months) from the analysis, a significant 
association was observed between clearance o f resistant parasites and age 
(P =0.043). Children in the age group 25-49 months are more likely to clear 
resistant parasites than younger children (6-12 months). However, it was 
observed that children aged 6-12 months old are better at clearing resistant 
parasites than children aged 13-24 months old though this was not statistically 
significant. This could be because younger children still retain some anti­
parasite protective immunity from maternal antibodies. The maternal 
antibodies could have waned in children aged 13-24 months old and they have 
not had time to develop a significant and effective anti-parasite immunity 
themselves. Since malaria transmission in the study area is holoendemic, 
children were highly exposed. This could account for the increased rate o f 
clearance o f resistant parasites in the older age group (25-49 months old) due 
to age acquired immunity.
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success. In support o f this hypothesis prior to the introduction o f  SP/CQ as the 
first line drug, CQ treatment failure rates were in excess o f 30 % (Talisuna et 
al., 2002), whereas the combination drug gave an adequate clinical response 
rate o f 92 %.
4.3. The role of mutations in DHFR in resistance to SP and SP/CQ
Mutations in DHFR  are clearly linked to resistance to pyrimethamine and to 
SP. The key mutation at position 108 (serine to asparagine) was present in all 
patients in whom treatment was unsuccessful, both pre- and post-treatment 
with SP/CQ and SP alone. None o f the patients had parasites with the wild 
type allele Z)77Fi?108Ser.
Samples from patients in whom SP/CQ was successful in clearing infection 
have not been typed, but typing o f other Ugandan samples from Tororo, Apac, 
and Kyenjojo suggests that the D iïF R lOSAsn is at or close to fixation (> 90%) 
in this population (Unpublished data). There was obviously no correlation 
with time to treatment failure and the presence o f different alleles at DHFR 
108 in the pre-treatment sample, since all pretreatment parasites carried the 
lOSAsn-encoding allele. The same trend was observed with both pre- and 
post-treatment samples from SP arm treatment failures.
Two other mutations in DHFR  in codons 51 and 59 have been linked to SP 
resistance.
For codon 51, the majority o f parasites typed had the mutant form encoding 
51 He. Infections with purely the mutant form o f codon 51 (51 He) were found 
in over 95% o f both pre- and post-treatment samples from patients in whom 
SP/CQ failed to clear parasitaemia, and in over 80% of pre- and post-treatment 
samples from patients in whom SP alone failed to clear parasitaemia. Mixtures 
o f wild type (51Asn) and mutant (51 He) parasites were found in two samples, 
one pre-treatment isolate in the SP/CQ arm, and one post-treatment isolate in 
the SP arm. A pure wild type infection was found in one patient with SP post­
treatment failure. Because the majority o f infections carried only the mutant 
allele, there was statistically no significant association between the presence o f
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different pre-treatment DHFR  51 alleles and the time to recrudescence or 
treatment failure in either SP/CQ or SP- treated patients.
For codon 59, the frequencies o f wild type (59Cys) and mutant (59 Arg) alleles 
were more evenly balanced: the majority o f pre-treatment samples from 
SP/CQ and SP treatment failures had a mixture o f wild type and mutant 
alleles, (17/22 and 19/33 respectively). Infections with only the wild type 
allele or only the mutant allele were found in a small number o f pretreatment 
patients in both drug treatment regimes.
There was evidence for selection o f  parasites carrying the mutant genotype 
DHFR59Arg following treatment with SP/CQ. O f the 17 patients with both 
parasites with wild type (59Cys) and mutant (59Arg) alleles prior to treatment, 
half o f them (8/17) had only parasites with the mutant allele at recrudescence, 
with the remainder unchanged as mixtures. The increase in prevalence o f pure 
infections o f DHFR59Arg, and decrease in mixed infections o f  wild type and 
mutant alleles was statistically significant (P=0.033). Further support for 
selection o f parasites carrying DHFR59Arg was obtained in the SP arm o f the 
study. Nineteen out o f 33 patients had mixtures o f wild type (59Cys) and 
mutant (59Arg) parasites prior to treatment, and 12 o f these had only parasites 
with the mutant allele encoding 59Arg at recrudescence. It is also noteworthy 
that five o f eight samples with apparently only parasites carrying DHFR59Cys 
at admission were found with parasites carrying only DHFR59Arg at 
recrudescence. These samples appeared to be genuinely recrudescent by MSP I  
and MSP2 genotyping. One explanation for this is that parasites carrying 
59Arg were present in the patient at admission, but were either at too low a 
parasitaemia to detect, or were not in periphery at time of sampling. Selection 
following SP treatment favored 59Arg parasites, so that their number 
increased to detectable levels by the time of clinical or parasitological 
treatment failure.
Analysis o f time to recrudescence showed that patients with parasites carrying 
pure DHFR59Arg in the DO sample recrudesced significantly earlier than 
those with a mixture o f DHFR  59Cys + 59Arg or those with pure
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DHFR59Cys. This was true only for the SP arm o f the study; it was not 
observed with the SP/CQ arm of the study, possibly because o f the low 
numbers o f parasites recrudescing early (< 14 days) in the latter arm.
It has been reported that combinations o f mutations in DHFR are associated 
with SP treatment failure in vivo. Patients carrying infections with pure 
108Asn/51Ile did not suffer recrudescence o f parasitaemia significantly earlier 
than those with mixtures o f wild type and mutant parasites following treatment 
with SP/CQ or with SP alone. However, the low P value o f 0.088 may indicate 
a possible association which could be investigated further with a larger sample 
size, although in this case the trend was for patients with the double mutant 
108Asn/51Ile to suffer recrudescences later than patients with parasites with 
other combinations.
Patients carrying infections o f pure jDiTFi?108Asn/59Arg double mutant 
parasites had significantly earlier recrudescences following SP treatment than 
those with other alleles (P=0.0016). There was no significant difference in the 
patients treated with SP/CQ, possibly because very few patients in this drug 
treatment arm had early treatment failure (recrudescence before day 14 post 
treatment). Patients carrying infections o f pure triple mutant 
(D7/F7( 108A sn/51 Ile/59Arg) recrudesced significantly earlier than patients 
with other infections in the SP drug treatment arm (P=0.0009), but not in the 
SP/CQ treated patients (P= 1.000), for the same reasons discussed above. For 
the SP-true recrudescent subset, even with the low numbers, there was still an 
association with the triple mutant and early recrudescence.
4.4. Conclusions
The aim o f this study was to tackle the question 'why do some patients 
progress to treatment failure much earlier than others?' by investigating if  the 
number o f mutations in the pyrimethamine resistance gene DHFR  had any 
influence on how fast a patient progressed to treatment failure.
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It is thought that mutations accumulate in DHFR, starting with changes to
codon 108, and that each additional codon change increases the level o f -
resistance (Peterson et al., 1990). This study has attempted to investigate the
role o f double and triple mutant forms o f  DHFR  in clinical treatment failure.
The results show that parasite infections o f pure double mutant 
(DjTFR 108Asn/59Arg) are associated with significantly earlier recrudescence 
following treatment with SP. Infections with parasites carrying the triple 
mutant form alone (D7/F7H 08Asn/51 He/59Arg) are even more significantly 
associated with early treatment failure.
The research presented here provides the first evidence that the number of 
mutations present in DHFR  has a significant effect on the type o f treatment 
failure (early vs. late, or RII/RIII vs RI) following SP chemotherapy. This has 
been previously assumed to be the case, but had not been formally 
demonstrated, although the association between any treatment failure and 
mutations in DHFR  is well known. Mutations in DHPS have also been shown 
to be implicated in resistance to SP in vivo in several places (Triglia et al., 
1997, Plowe et al., 1997, Wang et al., 1997a). There is also an observation 
that the emergence o f DHPS  mutations on a background o f pre-existing DHFR 
mutations coincided with the development o f increased SP resistance. (Roper 
et a l,  2003, Mberu et al., 2000, Nzila et a l ,  2000, Curtis et a l ,  1998, Plowe et 
a l,  1997). Due to financial constraints, this study did not investigate the 
association between mutations in DHPS and clinical treatment failure 
following treatment with SP. It is therefore not possible to tell whether the 
observed treatment outcomes based on the presence o f the double or triple 
mutant in DHFR  are independent/ or dependent on mutations in DHPS. 
Therefore, future studies using larger sample sizes and including DHPS 
genotyping should be undertaken in order to investigate the effect o f  DHPS 
mutations on clinical treatment failure in patients possessing double or triple 
mutations in DHFR.
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The timing o f recrudescence or treatment failure could also be due to different 
proportions o f drug-resistant and -sensitive parasites in the initial infection. 
The different types o f recrudescence seen could be the result o f within-host 
parasite population changes, or may reflect differences in the level of 
resistance. RI (late) recrudescence could be a result o f infection with weakly 
resistant parasites, which are affected by the drug so that they replicate more 
slowly, or only a proportion o f them survive. An RIII recrudescence could be 
due to highly resistant parasites which are unaffected by drug treatment. 
Alternatively, RI recrudescence could reflect an initial infection with both 
drug-sensitive and drug-resistant parasites, where the driig-resistance parasites 
represent the minority o f the parasites present. After treatment with the drug, 
only the resistant parasites in the RI infection would survive, the overall 
parasitaemia would be markedly reduced, and it would take more time for the 
parasitaemia to reach detectable levels and/or the threshold for recurrence of 
clinical symptoms. A patient suffering a rapid RIII recrudescence could have 
an infection where all or the majority o f parasites are resistant to the drug used 
for treatment. Infections with a majority o f resistant parasites might be 
expected to recrudesce sooner than those where the majority o f parasites are 
not resistant, and are killed by the drug. This has not been investigated in this 
study, but will form the basis o f future work using techniques such as in situ 
PCR (Ranford-Cartwright and Walliker, 1999) and quantitative PCR (Bell and 
Ranford-Cartwright, 2002).
Additional findings o f this work are that the drug combination SP/CQ had a 
lower treatment failure rate and a higher parasite clearance rate than SP alone 
in the population studied. This was unexpected given the high treatment 
failure rates previously observed using CQ as monotherapy, and the high 
prevalence (100%) o f  the Pfcrt mutation linked to CQ treatment failure in 
these patients. The most probable explanation o f this finding is that there are 
mutations in other genes, which are associated with CQ resistance in this area. 
Mutations in such genes would need to be coupled with mutations in DHFR
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for resistance to the combination o f both drugs, and where this is not the case 
the SP/CQ drug combination will be relatively more effective than SP alone.
The findings as discussed above, will help in laying strategies that will lead to 
the delay o f the spreading o f antimalarial drug resistance in Uganda. The 
Ministry o f Health in conjunction with the Malaria Control Programme will be 
able to use this information to adequately modify the national drug policy or 
distribute the available resources properly in order to preserve their efficacy. 
These findings will eventually help in the designing o f an affordable and 
effective therapy for the treatment o f malaria not only in Uganda but also in 
the rest o f sub-Saharan Africa.
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